Anna Suk-Fong Lok, M.D., F.R.C.P., AGAF, FAASLD Alice ...Consulting Positions Page 15 Visiting...
Transcript of Anna Suk-Fong Lok, M.D., F.R.C.P., AGAF, FAASLD Alice ...Consulting Positions Page 15 Visiting...
Anna Suk-Fong Lok 12/5/2016 1
Table of Contents
Anna Suk-Fong Lok, M.D., F.R.C.P., AGAF, FAASLD
Alice Lohrman Andrews Research Professor in Hepatology
Assistant Dean for Clinical Research
Professor of Internal Medicine and Director of Clinical Hepatology
Department of Internal Medicine
Division of Gastroenterology
University of Michigan Health System
1500 East Medical Center Drive
3912 Taubman Center, SPC 5362
Ann Arbor, MI 48109
Tel: 734-936-7511
Fax: 734-936-7392
Title and Contents Page 1
Education and Training Page 2
Certification and Licensure Page 2
Academic, Administrative, and Clinical Appointments Page 3
Research Interests Page 4
Grants Page 4
Honors and Awards Page 6
Memberships and Offices in Professional Societies Page 8
Editorial Positions, Boards, and Peer-Review Service Page 9
Teaching Page 11
Trainees Page 11
Committee, Organizational, and Volunteer Service Page 14
Consulting Positions Page 15
Visiting Professorships, Seminars, and Extramural Invited Page 16
Presentations
Bibliography Page 20
Anna Suk-Fong Lok 12/5/2016 2
CURRICULUM VITAE
Anna Suk-Fong Lok, M.D.
Division of Gastroenterology
University of Michigan Health System
3912 Taubman Center, SPC 5362
Ann Arbor, MI 48109
Tel: 734-936-7511
Fax: 734-936-7392
Education and Training
09/1972-05/1977 M.B., B.S., University of Hong Kong School of Medicine, Hong Kong
11/1990 M.D., University of Hong Kong School of Medicine, Hong Kong
11/1983 MRCP, Royal College of Physicians, U.K.
09/1991 FRCP, Royal College of Physicians, Edinburgh, U.K.
POSTDOCTORAL TRAINING
07/1977-06/1978 Internship in Medicine and Surgery, Queen Mary Hospital, Hong Kong
10/1978-06/1980 Residency in Internal Medicine, Queen Mary Hospital, Hong Kong
07/1980-08/1981 Fellowship in Gastroenterology, Queen Mary Hospital, Hong Kong
11/1981-11/1983 Fellowship in Hepatology, Royal Free Hospital, London, U.K. (under
Prof. Dame Sheila Sherlock and Prof. Howard C. Thomas)
03/1984 Department of Microbiology and Immunology, University of California,
San Francisco, USA, in molecular biology techniques (under Prof. H.E.
Varmus)
08/1985 Department of Microbiology, University of Southern California, Los
Angeles, USA, in molecular biology techniques (under Dr. T.Y.K. Fung)
SENIOR POSTDOCTORAL TRAINING
08/1988-09/1989 Sabbatical leave (with Dr. J.L. Gerin) in Georgetown University,
Division of Molecular Virology and Immunology
Certification and Licensure
DEA# BL3081700
Anna Suk-Fong Lok 12/5/2016 3
Michigan State L# 4301067002
Academic, Administrative and Clinical Appointments
Academic Appointments
10/1978-08/1981 Lecturer in Medicine, Department of Medicine, University of Hong Kong,
Queen Mary Hospital, Hong Kong
11/1981-11/1983 Hon Lecturer in Medicine, Academic Department of Medicine, Royal Free
Hospital, London, UK
12/1983-09/1987 Lecturer in Medicine, Department of Medicine, University of Hong Kong,
Queen Mary Hospital, Hong Kong
09/1987-08/1988 Senior Lecturer in Medicine, Department of Medicine, University of Hong
Kong, Queen Mary Hospital, Hong Kong
08/1988-08/1989 Visiting Associate Professor, Division of Molecular Virology and
Immunology, Georgetown University, Maryland, USA
09/1989-09/1990 Senior Lecturer in Medicine, Department of Medicine, University of Hong
Kong, Queen Mary Hospital, Hong Kong
09/1990-04/1992 Reader in Medicine, Department of Medicine, University of Hong Kong,
Queen Mary Hospital, Hong Kong
04/1992-06/1994 Associate Professor of Medicine, Tulane University School of Medicine,
Staff Physician, VA Medical Center, New Orleans, LA, USA
07/1994-09/1995 Professor of Medicine, Tulane University School of Medicine, Staff
Physician, VA Medical Center, New Orleans, LA, USA
10/1995-Present Professor of Internal Medicine, University of Michigan Medical Center,
Ann Arbor, MI, USA
Administrative Appointments
07/1996-08/2002 Medical Director of Liver Transplant Program, University of Michigan
Medical Center, Ann Arbor, MI, USA
10/1995-Present Director of Clinical Hepatology, University of Michigan Medical Center,
Ann Arbor, MI, USA
02/2008-08/2016 Associate Chair for Clinical Research, Department of Internal Medicine,
University of Michigan Medical Center, Ann Arbor, MI, USA
03/2016-Present Assistant Dean for Clinical Research, University of Michigan Medical
School, Ann Arbor, MI, USA
Clinical Appointments
10/1995-06/2001 Staff Physician, VA Medical Center, Ann Arbor, MI, USA
Anna Suk-Fong Lok 12/5/2016 4
Research Interests
Dr. Lok’s clinical research is focused on the natural history and treatment of chronic hepatitis B
and C as well as prevention and early detection of hepatocellular carcinoma (HCC). Her
laboratory research is focused on the role of hepatitis B virus genotypes and molecular variants in
the pathogenesis of HBV-related liver disease and response to antiviral therapy, and the evolution
of antiviral drug-resistant HBV. The key areas of her current research are listed below:
Hepatitis B
Evaluation of new therapeutic agents for chronic hepatitis B
Role of HBV genotypes and molecular variants in pathogenesis of HBV-related liver disease and
response to treatment
Mechanisms of HBV-related HCC
Changing epidemiology of HBV infection in North America
Hepatitis C
Evaluation of new treatment for chronic hepatitis C
Evaluation of non-invasive assessment of hepatic fibrosis
Predictors of HCV progression
Epidemiology and natural history of chronic hepatitis C in the US and China and factors
contributing to differences in HCV-related HCC in the two countries
HCC
Evaluation of risk factors for HCC
Evaluation of biomarkers for detection of early HCC
Grants
Current (Direct cost; current year only)
2008-2020: NIH U01 DK082863 (+ 2 supplemental awards). Hepatitis B Clinical Research
Network Clinical Center: Michigan – Hawaii Consortium. $368,069 (Lok, PI and chair of
steering committee), 27% effort.
2012-2017: Bristol-Myers Squibb - A Long-Term Follow-up Study of Subjects Who Participated
in a Clinical Trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was
Administered for the Treatment of Chronic Hepatitis C. ~$25,000 (Lok, PI), <1% effort.
2012-2017: University of Florida – HCV-Target: Hepatitis C Therapeutic Registry and Research
Network – A longitudinal, observational study. ~$100,000 (Lok, PI), 1% effort.
Anna Suk-Fong Lok 12/5/2016 5
2013-2018: Bristol-Myers Squibb: Predictors of HCV Progression. ~$130,000 (Lok, PI), 4%
effort.
2014-2017: Gilead: A long term follow-up registry study of subjects treated in a Gilead-
sponsored trial with chronic hepatitis B infection. ~$12,000 (Lok, PI) <1% effort.
2015-2018: PCORI PROP-up TARGET: The Patient-Reported Outcomes Project of HCV-
Target. ~$260,000 (Lok, coI; PI: Evon [UNC]), <1% effort.
2015–2019: VA CSR&D MERIT REVIEW. Does screening for HCC reduce HCC-related
mortality in HBV-infected Veterans? (Ioannou, PI), unpaid consultant.
2015-2019: 1R01CA196692-01, NIH/NCI. Does Screening for HCC in Cirrhotic Patients
Reduce HCC-related Mortality? (Ioannou, PI), unpaid consultant.
2016-2018: University of Michigan Health System-Peking University Health Sciences Center
Joint Institute for Clinical and Translational Research: Role of visceral adiposity and gut
microbiome in the pathogenesis of non-alcoholic fatty liver disease in lean versus obese patients:
a comparative study between patients at UMHS versus PUHSC. $145,000 (Lok, PI), 5% effort.
2015-2017: Gilead: A phase 3, global, multicenter, randomized, double-blind, placebo-controlled
study to investigate the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed-dose
combination for 12 weeks in direct-acting antiviral-experienced subjects with chronic HCV
infection. ~$50,000 (Lok, PI) 1% effort.
2015-2017: Gilead: A phase 3, global, multicenter, randomized, open label study to investigate
the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed-dose combination for 8 weeks
compared to sofosbuvir/velpatasvir for 12 weeks in direct acting antiviral-naïve subjects with
chronic HCV infection. ~$75,000 (Lok, PI) 1% effort.
2016-2017: Gilead: A phase 3, global, multicenter, randomized, open labeled study to investigate
the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed dose combination for 8 weeks
and sofosbuvir/velpatasvir for 12 weeks in subjects with chronic genotype 3 HCV infection and
cirrhosis. ~$40,000 (Lok, PI) <1% effort.
2016-2018: Gilead: A phase 3, global, multicenter, randomized, open label study to investigate
the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed dose combination for 12 weeks
and sofosbuvir/velpatasvir for 12 weeks in direct acting antiviral experienced subjects with
chronic HCV infection who have not received an NS5A inhibitor. ~$20,000 (Lok, PI) <1%
Anna Suk-Fong Lok 12/5/2016 6
effort.
2016-2021: PCORI: PRIORITIZE STUDY: A pragmatic, randomized study of oral regimens for
hepatitis C: transforming decision-making for patients, providers and stakeholders. $123,150 (U
Florida: Nelson, PI, Lok co-I) 5% effort.
2016-2023: Target PharmaSolutions, Inc: A 5-year longitudinal observation study of patients
with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. ~$120,000 (Lok PI) 1%
effort.
2013-2021: Gilead Sciences: A Long Term Follow-up Registry for Subjects Who Achieve a
Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic
Hepatitis C Infection. ~$12,000 (Fontana, PI, Lok co-I) <1% effort.
Mentee grants
2016-2018: American Association for the Study of Liver Diseases Foundation – Clinical and
Translational Research Award to Jessica Mellinger, MD (clinical lecturer), $75,000
Honors and Awards
1974 Janet McClure Kilborn Prize in Physiology and Biochemistry
1977 Distinctions in Medicine, Pediatrics, Obstetrics and Gynecology
1977 Gordon King Prize in Obstetrics and Gynecology
1977 RM Gibson Gold Medal in Pediatrics
1977 Chan Kai Ming Prize for the best performance in the final MB
examination
1977 Proxime Accessit to the Anderson Gold Medal for the second highest
aggregate score in all MB examinations
1977 Hong Kong University Alumni Association Prize for the most outstanding
graduate of the year
1985-1987 Young Investigator Award at the 1st, 2nd and 3rd Annual Scientific
Meetings of the Hong Kong Society of Gastroenterology
1990 Best Free Paper Award at the Annual Scientific Meeting of the Hong
Kong College of Physicians
1991 Sir Patrick Manson Gold Medal for outstanding M.D. Thesis
1992 First AJS McFadzean Memorial Lecture Prize, Combined Scientific
Meeting, Royal College of Physicians (London, UK) and Hong Kong
College of Physicians
1992-1993 Owl Club Award, Tulane University, for Outstanding Clinical Teacher
1996 Hugh R. Butt Award for Distinguished Achievement in Clinical Research
in Hepatology, American Digestive Health Foundation
Anna Suk-Fong Lok 12/5/2016 7
1998 Lotus Award, University of Michigan, United Asian American Medical
Students Association for Outstanding Guidance and Support to Students
2001 Distinguished Physician Award, Chinese American Physician Society
2002 Singapore Ministry of Health Visiting Expert on Health Care and
Research in Liver Disease
2002 University of Texas Southwestern Medical Center, 6th
Annual Visiting
Professorship for an Outstanding Internationally Recognized Female
Scientist/Clinician/Health Care Worker.
2004 Lotus Award, University of Michigan, United Asian American Medical
Students Association for Outstanding Guidance and Support to Students
2005-2010 Bristol-Myers Squibb Foundation Freedom to Discover Virology Award
2005 Community Health Charities “Outstanding contribution to health” Award
in recognition of work on promoting awareness and education on
hepatitis B among Asian Americans through the THINK B Campaign
organized by the American Liver Foundation
2007 Outstanding Teacher Award, University of Michigan, Gastroenterology
Fellows, Class of 2007
4/2008 Distinguished Scientist Award, Hepatitis B Foundation
5/2008 Outstanding Women in Science, American Gastroenterological
Association Foundation
10/2008 Alice Lohrman Andrews Research Professor in Hepatology, University of
Michigan
6/2009 Outstanding Teaching Award, University of Michigan, Gastroenterology
Fellows, Class of 2009
9/2010 Okuda Award, Asian-Pacific Digestive Week (Kuala Lumpur, Malaysia)/
Journal of Gastroenterology and Hepatology
6/2011 League of Research Excellence, University of Michigan Medical School
6/2011 Scopus Award, Elsevier / International Digestive Disease Forum, Chinese
University, Hong Kong.
11/2011 Distinguished Service Award, American Association for Study of Liver
Diseases
3/2012 Distinguished Mentor Award, Michigan Institute of Clinical and Health
Research, University of Michigan (CTSA)
4/2012 Member, Association of American Physicians (inducted April, 2012)
10/2012 British Medical Association Book Award 2012 – First prize in Internal
Medicine Category
3/2013 Member, Clinical Excellence Society, University of Michigan Medical
School, Department of Internal Medicine
7/2013 Hepatitis Champion, Viral Hepatitis Action Coalition (CDC/HHS and
others), DC
Anna Suk-Fong Lok 12/5/2016 8
8/2014 Thomson Reuters list of most-cited researchers in the world (top 1% by
citations in Web of Science database) for the period 2002-2012
9/2014 American Medical Association Women Physicians Section Inspirational
Physician Award
10/2015 Chinese Hospital, San Francisco, 42nd
Annual Distinguished Physician
Award
11/2015 American Liver Foundation, Distinguished Scientific Achievement Award
5/2016 American Gastroenterological Association, William Beaumont Prize in
Gastroenterology
Memberships and Offices In Professional Societies
1981-1995 Hong Kong Society of Gastroenterology
1985-1995 Gastroenterological Society of Australia
1986-1995 Asian Pacific Association for the Study of the Liver
1986-1995 International Association for the Study of the Liver
1987- European Association for the Study of the Liver
1988- American Association for the Study of Liver Diseases
1988- Hong Kong Association for the Study of Liver Diseases
1994- Southern Society for Clinical Investigation
1996- American Gastroenterology Association
American Association for the Study of Liver Diseases
1993-1996 Member, Publications Committee
1995-1996 Member, Abstract Selection Committee, Hepatitis non-C
1996-1998 Chair, Abstract Selection Committee, Hepatitis, non-C
1997 Member, Nomination Committee
1998-2000 Member, Abstract Selection Committee, Hepatitis B
1999-2001 Member, Clinical Research Committee
2000-2002 Chair, Abstract Selection Committee, Hepatitis B Treatments
2001-2003 Councilor at large, Governing Board
2004-2005 Member, International Educational Committee
2005-2009 Member, Abstract Selection Committee, Hepatitis B
2011-2013 Member, Abstract Selection Committee, Hepatitis B Treatment
2013-2015 Councilor, Governing Board
2014 Chair, Abstract Selection Committee, Hepatitis B Virology and
Pathogenesis
2016 President-elect
2017 President
National Institutes of Health
Anna Suk-Fong Lok 12/5/2016 9
1996-1997 Member, Planning Committee, Consensus Development Conference on
‘Diagnosis and Management of Hepatitis C’, NIDDK
1996 NIAID, Collaborative Antiviral Study Group. Member, Hepatitis Advisory
Committee
1999-2000 Co-organizer, Advisory Workshop on ‘Management of Hepatitis B’,
NIDDK
2000 Member, Antiviral Resistance Task Force, NIAID
2004-2009 Member, Hepatitis Panel, US-Japan Medical Cooperative Program
2005-6 Co-organizer, Workshop on “Management of Hepatitis B – 2006”
2007 Member, Planning Committee, Consensus Development Conference on
“Management of Chronic Hepatitis B”, NIDDK
American Gastroenterology Association
1999-2000 Member, Committee on Women in Gastroenterology
2000-2003 Consultant, Gastroenterology Teaching Project on Viral Hepatitis
2006-2009 Member, AGA International Committee
2010-2013 Member, Research Award Panel
European Association for the Study of the Liver
1999 Member, Consensus Development Panel on Hepatitis C
2002 Member, Consensus Development Panel on Hepatitis B
American Liver Foundation
2004-2007 Member, National Board of Directors
2004-2007 Co-Chair, THINK B Program
2005-6 Chair, Hepatitis Council
Editorial Positions, Boards, and Peer-Review Service
Senior Associate Editor
2011-2012 Gastroenterology
Co-Editor
2007-2009 Journal of Viral Hepatitis
Associate Editor
2001-2006 Hepatology
Editorial Boards
1985-1993 Journal of Gastroenterology & Hepatology
Anna Suk-Fong Lok 12/5/2016 10
1991-2001 Hepatology
2000- Journal of Hepatology
2001- Antiviral Therapy
2004- Liver Transplantation
2009-2010 Annals of Internal Medicine
2009-2011 Gastroenterology
Journal Review
Hepatology
Gastroenterology
Journal of Hepatology
American Journal of Gastroenterology
Journal of Medical Virology
Journal of Viral Hepatitis
Annals of Internal Medicine
New England Journal of Medicine
Gut
JAMA
Grant Review
1992 Ad Hoc Reviewer, N1DDK RO1 Award
1996- Ad Hoc Reviewer VA Merit Review Award
1997-1998 Ad Hoc Reviewer NIAID K08, RO3 Award
1997 Ad Hoc Reviewer, NCI, PO1
1998-2002 Member, Study Section on Microbiology and Infectious
Diseases, NIAID
1999 Ad Hoc Reviewer, NIDDK, RFA on Hepatitis C
2000 Ad Hoc Reviewer, NIDA, RFA on Hepatitis C
2000 Research Grant Council, Hong Kong
2001 Ad Hoc Reviewer, Special Review on CASG, NIAID
2001-2002 Ad Hoc Reviewer, Special Review on Hepatitis C and Liver Transplant,
NIDDK
2002 Ad Hoc Reviewer, Wellcome Trust, U.K.
2003 Ad Hoc Reviewer, NIDDK, RFA on Hepatitis C
2004-2009 American Liver Foundation, Research Grants Review Committee
2004- Reviewer, NIAID and NIDDK Loan Repayment Program
2004 Ad Hoc Reviewer, NIAID HIV Study Section
2004 Ad Hoc Reviewer, NIDDK, Hepatobiliary Pancreatic Study Section
2005 Ad Hoc Reviewer, NIAID, AIDS Clinical Trials Leadership Network
2007 Ad Hoc Reviewer, Wellcome Trust, UK
Anna Suk-Fong Lok 12/5/2016 11
2009 Ad Hoc Reviewer, French National Cancer Institute
2009 Ad Hoc Reviewer, National Blood Service, UK
2009- Ad Hoc Reviewer, University and Polytechnic Grant Committee, Hong
Kong
2009 Ad Hoc Reviewer, NIDDK, ARRA Grants
2010 Ad Hoc Reviewer, NIDDK Hepatobiliary Pancreatic Study Section
2010 Chair, NIAID, Special Review – Novel therapies for bacterial and virus
infections
6/2011 Ad Hoc Reviewer, NIDDK, R21 panel
3/2012 Invited Reviewer, Danish National Technology Foundation
8/2011 Ad Hoc Reviewer, NIDDK, X01
3/2013 Ad Hoc Reviewer, VA HSR&D
8/2013 Ad Hoc Reviewer, NIDDK, X01
9/2013 Ad Hoc Reviewer, VA HSR&D
7/2015 Ad Hoc Reviewer, DOD grants on HBV
7/2016 Ad Hoc Reviewer, DOD grants on HBV
9/2016 Ad Hoc Reviewer, DOD grants on HBV
Teaching
1995- University of Michigan
Students:
Ambulatory clinics and attending rounds
Mentor:
UAAMSA 1996-
AMWA 1999-
Residents and Fellows:
Ambulatory clinics and attending rounds
Journal Clubs (4 times/year)
Case conferences (3 times/year)
In-Service lectures (6 / rounding month)
Morning Report (5/14, 4/15)
Others:
Medicine Grand Round (1/00, 8/11)
Lecture, University Health Service (4/97, 12/02, 1/03)
Course Co-Director and Lecturer AASLD Wrap-up (12/01, 11/02,
11/03, 12/04, 12/05, 12/06, 12/07, 12/08, 12/09, 12/10, 12/11, 12/12,
12/13, 12/14, 12/15, 12/16)
Lecturer, Liver Transplant Course (6/06, 4/07, 5/08, 5/09, 5/11, 5/12,
5/15)
Lecturer, General Medicine Morning conference (1/12)
Anna Suk-Fong Lok 12/5/2016 12
Lecturer, Internal Medicine Course (5/15)
Lecturer, Metabolism and Endocrine conference (5/15)
Trainees
Tulane University
Ulus S. Akarca, M.D. – 1993-1994
1994. Recipient of American Federation of Clinical Research Trainee
Travel Award
1994. Glaxo-American Gastroenterology Association Trainee Research
Award
Hakan Bozkaya, M.D. – 1994-1995
Marc G. Ghany, M.D. – 1993-1996
1995. Recipient of American Federation of Clinical Research Trainee
Travel Award
1996. American Federation of Clinical Research Junior
Faculty Award 1996
Consuelo Soldevila-Pico, M.D. – 1993-1995
1995. Recipient of American Federation of Clinical Research Trainee
Travel Award
Balu Chandra, M.D. – 1994-1995
1996. Recipient of American Federation of Clinical Research Trainee
Travel Award
University of Michigan
Naresh Gunaratnam, M.D. – 1996-1998
Robert J. Fontana, M.D. – 1996-2002
Thomas Shehab, M.D. – 1996-2002
1998. Recipient of Senior Medical Resident Research Award
1998. Recipient of Department of Internal Medicine Research Day
Award
1998. Recipient of ACP, Michigan Chapter Residents Oral Presentation
Award
2000-2001 NIH T32 Training Program
2001-2002. AASLD/Schering Hepatology Fellowship
Henry LY Chan, M.B., B.S. – 1997-1998
Hong Kong Association for Study of Liver Diseases Fellowship
Eng-Kiong Teo, M.D. – 1999-2000
Singapore Government Fellowship
Khozema Hussain, M.D. – 1999-2000
Schering Plough Hepatology Fellowship
Chi-Jen Chu, M.D. – 2000-2002
Anna Suk-Fong Lok 12/5/2016 13
Taiwan Government Fellowship
Jorge Marrero, M.D. – 2000-
2000-2001 AASLD Junior Faculty Award
2001-2003 AGA/ADHF Career Development Award
2001-2003 ACG Career Development Award (returned)
2001-2003 NIH K-30 trainee
2003-2004 University of Michigan/Pfizer Bridge Award for K30 graduate
2004-2009 NIH K23 award
Hari Conjeevaram, M.D. – 2001-2007
2001-2003 NIH K-30 trainee
Mary Ann Huang, M.D. – 2001- 2005
2001-2003 NIH K-30 trainee
2003-2004 AASLD/Schering Advanced Hepatology Fellowship
2003-2004 University of Michigan/Pfizer Bridge Award for K30 graduate
2004-2005 AASLD Jan Albrecht Clinical Research Award
Desmond C.T. Wai, M.D. – 2002-2003
Singapore Government Fellowship
Scott K. Fung, M.D. – 2003 -2005
2003-2004 Canadian Association for the Study of the Liver Fellowship
2004-2005 Hepatitis Foundation International Epidemiology Fellowship
Award
2004-2005 Canadian Institutes of Health Research Fellowship
Hee Bok Chae, M.D. – 2004-2005
2004-2005 Bristol-Myers Squibb Virology Fellowship
Caryn Baldauf, M.D. – 2004-2005
Emmanuelle Depayre Williams, M.D. – 2005-2006
Hellan Kang, M.D. – 2004-
NIH T32 Training Program
Hyung Joon Yim, M.D. – 2005-2006
Korean Fellowship
Stephen Wong, M.D. – 2005-6
Asia Brewery Medical Specialty Scholarship, Philippines
Bristol-Myers Squibb Virology Fellowship
Melissa Osborn, M.D. – 2005-6
Emory University, Infectious Diseases Section
Michael Volk, M.D. – 2005-2014
2006-2008 Robert Wood Johnson Clinical Scholars Program
2008-2011 AGA Foundation Research Scholar Award
2010 –2015, NIH K23 award
Pratima Sharma, M.D. – 2005-
Anna Suk-Fong Lok 12/5/2016 14
NIH K30 / OJO trainee
NIDDK T32
American Transplant Society
2011 - NIH K08 award
Jessica Tan, M.D. – 2006-7
Singapore Ministry of Health and Changi General Hospital
Bulent Degertekein, M.D. – 2006 –8
2007-2008 Bristol Myers Squibb Foundation Virology Fellowship
Eric Orman, M.D. – 2007-9
Ed Chotiyaputta, M.D. – 2008-2010
Siriaj Hospital, Bangkok, Thailand
Eva Huang, M.D. – 2008-2013
Ravitz Foundation
Fausta Ditah, M.D. – 2009-2011
Chanunta Hongthanakorn, M.D. – 2009-2010
Military Hospital, Bangkok, Thailand
Andrew Tai, M.D., PhD – 2009-2014
2009-2011 AGA Research Scholar Award
2010- NIH K08 award
2013 – NIDDK R01
Mina Rakoski, M.D. – 2009-2015
NIH T32 Program
2011-2012 AASLD Advanced Hepatology Fellowship
2012-2013 AGA Emmet Keeffe Award
Cheng Wang, M.D. – 2011-2012
Alice Lohrman Andrews Research Professorship
Peng Hu, M.D. – 2012
Chung King Medical School, China
Suna Yapali, M.D. – 2012-4
Turkish Liver Association
Nizar Talaat, M.D. – 2012-4
Monica Konerman, M.D. – 2013 –
NIH T32 Program
Robert Wood Johnson Clinical Scholars Program
AASLD Advanced Hepatology Fellowship, 2015-2016
Jessica Mellinger, M.D. – 2013-
NIH T32 Program
Robert Wood Johnson Clinical Scholars Program
AASLD Advanced Hepatology Fellowship, 2014-5
AASLD Clinical and Translational Research Award, 2016-8
Anna Suk-Fong Lok 12/5/2016 15
Arpan Patel, M.D. 2014-2015
AASLD Emerging Liver Scholar Award
Rima Mohamad, Pharm D 2014
Mary Thomson, M.D. 2015-
Aashesh Verma, M.D. 2015-
AASLD Emerging Liver Scholar Award
Tony Feng, M.D. 2016-
Elliot Tapper, M.D. 2016-
Committee, Organizational, and Volunteer Service
Memberships in Intramural Research Centers and Programs
1995- Member, Research Advisory Committee, Education Committee, Clinical
Operations Committee, Division of Gastroenterology
1996-2000 Member, Transplant Center Operating Committee
1997-2001 Member, Promotions Committee, Department of Internal Medicine
2006 Member, Leadership Panel, Med IRB Lean Project
2006 Member, IRBMED ICD Template Clinical Research Billing Work Group
2007 Member, Clinical Trials Grant Review Panel, CTSA
2009 Clinical Research Pricing Tool, Medical School Office of Research
2009-2010 Member, Advisory Panel, Strategic Assessment of Clinical Research
Enterprise, MICHR
2010-2013 Member, PTSP and KL2 grant review panel, CTSA/MICHR
2010 Member, Advisory Panel, eThority and Clinical Billing, Medical School
Office of Research
2010 Member, Geriatrics Division Internal Review, Department of Internal
Medicine
2010-2013 Member, Contracting Deployment Advisory Committee, Medical School
Office of Research / MICHR
2012-2016 Member, Advisory Panel, University of Michigan Office of Human
Research Compliance Review (OHRCR)
2014- Member (Chair 5/2016- ), Clinical Trials Task Force, University of
Michigan Medical School Research Board of Directors (RBOD)
2014- Member, Advisory Board, Veterans Education and Research Association
of Michigan (VERAM)
Community/Volunteer Service
1998-2004 Advisor, Michigan Hepatitis C Support Group
2000-2003 Co-Chair, Medical Advisory Board, Michigan Chapter, American Liver
Anna Suk-Fong Lok 12/5/2016 16
Foundation
2005-2008 Advisor, PKIDS (Organization to Prevent Infectious Diseases in Children)
2006- Advisor, APAMSA (Asian Pacific American Medical Students
Association)
2006- 2012 Advisor, Healthy Asian Americans Program, School of Nursing,
University of Michigan
2006- Advisor, Asian Health Foundation
2008-2013 Member, Executive Board, Asian Health Foundation
Consulting Positions (Advisory Board, ad Hoc consulting, recent/active)
1998-2015 Gilead Sciences
2002-7, 2009-10 Bristol-Myers-Squibb
2003-2012 Hoffmann La Roche
2008-2013 Bayer (Data and Safety Monitoring Board)
2009-2015 GlaxoSmithKline (Hepatotoxicity Board)
2009-2010 Abbott (Data and Safety Monitoring Board)
2012 Achillon
2012 Astex
2012 Arrowhead
2012-2013 Janssen, Johnson & Johnson
2012-3, 2015 Merck
2012 Novartis
2013 Immune Targeting System
2013 MedImmune
2013-2015 Tekmira
Federal agencies, WHO and academic medical centers
2002 Consultant, Hepatitis B Antiviral Trials, FDA, CDER
2004 Consultant, Hepatitis B Immune Globulin in Liver Transplant Patients,
FDA, Biologics
2005- Member, External Advisory Board, Yale University Liver Center
2007- Consultant, CDC Viral Hepatitis Division
2011- Member, External Advisory Board, University of California San Francisco
Liver Center
2012-2015 Member, Hepatitis Guidelines Working Group, WHO, Geneva,
Switzerland
Visiting Professorships, Seminars, and Extramural Invited Presentations
State-of-the-art/Titled lectures
Anna Suk-Fong Lok 12/5/2016 17
03/1992 First AJS McFadzean Memorial Lecture, Hong Kong
10/1994 State-Of-The-Art lecture, World Congresses of Gastroenterology,
Los Angeles, CA
1995 Xth
Charles Brown Memorial Lecture, Cleveland Clinic, Cleveland, OH
04/1996 IVth
British Liver Trust Lecturer, Birmingham, UK
11/1996 Key-note Speaker, First National Congress of Hepatology, Istanbul,
Turkey
1995 Plenary Lecture, IX Triennial International Symposium on Viral Hepatitis
and Liver Diseases, Rome Italy
1996 Keynote Speaker, 6th
National Symposium on Hepatitis B and C.
Melbourne, Australia.
1998 ‘State-of-the-Art’ Lecture on Treatment of Hepatitis B. 3rd
International
Symposium on Therapy of Liver Diseases, Barcelona, Spain.
1999 James Lau Memorial Lecture, 4th
International Symposium on Viral
Hepatitis and Liver Cancer, Shanghai, China
2000 Plenary Lecture, X Triennial International Symposium on Viral Hepatitis
and Liver Diseases, Atlanta, GA
2001 Mizne Lecture, McGill University, Montreal, Canada
2002 6th
Annual Lectureship – Distinguished Women in Science/Medicine,
UTSW, Dallas, TX
2003 Plenary Lecture, XI Triennial International Symposium on Viral Hepatitis
and Liver Diseases, Sydney, Australia
2003 Stephen Winter Memorial Lecture – University of Illinois, Chicago
2004 AASLD State-of-the-art-lecture, DDW, New Orleans, LA
2005 Sheila Sherlock Liver Research Day Guest Speaker, University of Toronto,
Toronto, Canada
2006 State of the art lecture, Annual Hepatitis Symposium, Greek Liver
Association, Athens, Greece
2007 21st Klatskin lecture, Yale University, New Haven, CT
2008 14th
Leon Schiff lecture, University of Miami, Miami, FL
9/2010 Okuda Lecture, Asian Pacific Digestive Week, Kuala Lumpur, Malaysia
6/2011 1st Scopus Lecture, International Digestive Forum, Hong Kong
5/2012 AASLD State of the Art Lecture – Hepatitis B: Who to treat and Who can
wait? DDW, San Diego, CA
10/2012 27th Leon Schiff Lecture – Hepatitis B Treatment, University of
Cincinnati, Cincinnati, OH
11/2012 President’s Choice Lecture – Progress in Hepatitis B: A journey from 1982
to 2012, 63rd
AASLD annual meeting, Boston MA
10/2014 Wade Volwiler Visiting Professor, lecturer at Medicine Grand Rounds –
Hepatitis B Progress and GI Grand Rounds – Lessons learned from
Anna Suk-Fong Lok 12/5/2016 18
Hepatitis B Research Network, University of Washington, Seattle, WA
12/2014 William and Rebecca Balistreri Lecturer – Hepatitis C Cure, How to
Apply the Tools we Have, Cincinnati Children Hospital, Cincinnati, OH
2/2015 Andres Blei Memorial Lecturer – Towards Global Elimination of Hepatitis
B, Northwestern University, Chicago, IL
4/2015 Fenton Schaffner Lecturer – New lessons about an ancient disease:
Lessons learned from Hepatitis B Research Network, Mount Sinai Icahn
School of Medicine, New York, NY
5/2015 Raj and Prem Goyal Lecturer – Implementation of Hepatitis C Cure.
Boston VA Medical Center, Boston, MA
5/2016 Pfeiffer Diversity Visiting Professor – Progress in Hepatitis B - Stanford
University Medical School, Palo Alto, CA
11/2016 Leon Schiff State-of-the-art Lecture – Elimination of hepatitis B: is it
possible? American Association for the Study of Liver Diseases Annual
Meeting, Boston, MA
12/2016 8th
Reynolds Memorial Lecturer – Treatment of hepatitis B: current status
and prospects for cure - University of Southern California, Los Angeles,
CA
National (from 2011)
1/2011 Moderator and Invited Speaker, AGA Clinical Congress, Miami, FL
1/2011 Visiting Professor and GI Grand Rounds Speaker, University of Colorado,
Aurora, CO
2/2011 Invited Speaker, American Chinese Medical Association Annual Scientific
Meeting, Boston, MA
4/2011 Invited Speaker, Medicine Grand Rounds, Bronson Hospital, Kalamazoo,
MI
6/2011 Course Director, moderator and speaker, AASLD-CDC Single Topic
Conference on Viral Hepatitis, Atlanta, GA
11/2011 Invited Speaker, Postgraduate Course; and Moderator, Parallel Free Paper
Session, AASLD Annual Meeting, San Francisco, CA
12/2011 Invited Speaker and Moderator, HepDart, Kauai, HI
1/2012 Invited Speaker and Moderator, AGA Clinical Congress, Miami, FL
2/2012 Invited Speaker, GI/Liver Conference, Honolulu, HI
3/2012 Invited Speaker, Medicine Grand Rounds, and ID Conference, University
of Massachusetts, Worcester, MA
3/2012 Invited Speaker, Grand Rounds, Antiviral and Drug Hepatotoxicity
Divisions, FDA, Silver Spring, MD
3/2012 Invited Speaker, Scripps Clinic Liver Course, La Jolla, CA
Anna Suk-Fong Lok 12/5/2016 19
4/2012 Invited Speaker, Medicine Grand Rounds, Bronson Hospital, Kalamazoo,
MI
5/2012 Invited Speaker, DDW Postgraduate Course and Moderator, DDW
Clinical Challenge Session, San Diego, CA
5/2012 Invited Speaker, GI Grand Rounds, University of Connecticut,
Farmington, CT
7/2012 Invited Speaker, Symposium on HCV Direct Acting Antivirals, San
Francisco, CA
9/2012 Invited Speaker, GI Conference, Stanford University, Palo Alto, CA
11/2012 Invited Speaker, Postgraduate Course, and President’s Choice Lecture,
AASLD annual meeting, Boston, CA
1/2013 Invited Speaker, AGA Clinical Congress, San Diego, CA
1/2013 Lecturer, Web lecture, Charles B. Wang Community Health Center, New
York, NY
2/2013 Invited Speaker, GI Conference, University of Chicago, Chicago, IL
2/2013 Invited Speaker, Update in Hepatology, University of Miami, Miami, FL
2/2013 Lecturer, Web lecture, VA Health System, national
3/2013 Invited Speaker and Moderator, AASLD Emerging Trends Conference on
Reactivation of Hepatitis B, Crystal City, VA
4/2013 Invited Speaker, UCSF Liver Center Annual Meeting, San Francisco, CA
4/2013 Invited Speaker, GI Grand Rounds and Research Forum, Baylor University
Medical Center, Houston, TX
4/2013 Invited Speaker, Medicine Grand Rounds, MD Anderson Medical Center,
Houston, TX
5/2013 Invited Speaker, Liver Update, Yale University, Westport, CT.
5/2013 Invited Speaker, Postgraduate Course, Digestive Disease Week, Orlando,
FL.
12/2013 Invited Speaker and Moderator, HepDart Symposium, Kona, HI
3/2014 GI and Liver Symposium, Virginia Commonwealth University, Richmond,
VA
4/2014 Invited Lecturer, Medicine Grand Rounds, Bronson Hospital, Kalamazoo,
MI
5/2014 Invited Speaker, International Conference on Antiviral Resistance,
Raleigh, NC
10/2014 Invited Speaker, Seattle Gut Club, Seattle, WA
11/2014 Invited Speaker, Liver Symposium, Brooklyn, NY
1/2015 Invited Speaker, ASCO GI Cancer Symposium, San Francisco, CA
3/2015 Invited Speaker, GI/Liver Update, University of Pennsylvania,
Philadelphia, PA
10/2015 Invited Speaker, Annual Distinguished Awardee Lecture, Chinese
Anna Suk-Fong Lok 12/5/2016 20
Hospital, San Francisco, CA
10/2015 Invited Speaker, Liver Symposium, Loma Linda University, Palm Springs,
CA
11/2015 Moderator – Postgraduate Course and Late Breaker session, Invited
Speaker – Hepatology Associates Course and HBV Special Interest Group
Symposium, AASLD Annual Meeting, San Francisco, CA
12/2015 Invited Speaker, Academy of Medicine Conference on Hepatitis B and C,
Washington, DC.
12/2015 Invited Speaker and Moderator, HepDART symposium, Maui, HI
3/2016 Moderator, AGA-AASLD Academic Skills Workshop, Phoenix, AZ
3/2016 Invited Speaker, GI Grand Rounds, Cleveland Clinic, Cleveland, OH
5/2016 Invited Speaker and Moderator, Digestive Diseases Week, San Diego, CA
8/2016 Invited Speaker, GI Grand Rounds, Indiana University, Indianapolis, IN
9/2016 Course Director, Moderator and Speaker, AASLD-EASL HBV Treatment
Endpoint Workshop, Alexandria, VA
9/2016 Invited Speaker, AASLD Liver Transplant Board Review Course,
Chicago, IL
11/2016 Moderator and Speaker, AASLD Annual meeting, Boston, MA
International (from 2011)
2/2011 Moderator and co-Director, Cost-effectiveness of HBV Treatment
Workshop, APASL annual meeting, Bangkok, Thailand
3/2011 Invited Speaker and Moderator, Professor Howard Thomas Festschrift,
Imperial College & St. Mary’s Hospital, London, UK
3/2011 Invited Speaker, Virgil Symposium, EASL annual meeting, Berlin,
Germany
6/2011 Invited Speaker and moderator, International Digestive Disease Forum,
Hong Kong
9/2011 Invited Speaker, International Liver Cancer Association, Hong Kong
9/2011 Moderator, International Symposium on Therapy in Liver Diseases,
Barcelona, Spain
11/2011 Invited Speaker, Update in Hepatology, Milan, Italy
2/2012 Invited Speaker and Moderator, APASL annual meeting, Taipei, Taiwan
4/2012 Invited Speaker, HBV Symposium and Highlights of 2011, EASL annual
meeting, Barcelona, Spain
6/2012 Invited Speaker, Hepatitis Conference, St. Petersburg, Russia
6/2012 Plenary Speaker, 14th
Triennial Symposium on Viral Hepatitis and Liver
Disease, Shanghai, China
6/2012 Invited Speaker, Hepatitis C Conference, Peking University, Beijing,
Anna Suk-Fong Lok 12/5/2016 21
China
7/2013 Invited Speaker, Conference celebrating 50th
anniversary of discovery of
HBsAg, Peking University, Beijing, China
7/2013 Invited Speaker, Changing Landscape of HCV Treatment, 302 Hospital,
Beijing, China
8/2013 Invited Speaker, Liver Symposium and DS Chen Retirement Festschrift,
Taiwan Association for the Study of the Liver, Taipei, Taiwan
10/2013 Invited Speaker, Liver Symposium and EJ Heathcote Retirement
Festschrift, University of Toronto, Toronto, Canada
4/2014 Invited Speaker, HBV and HCV Symposium, EASL annual meeting,
London, UK
6/2014 Invited Speaker, 2014 Liver Week, Joint Symposium of Korean
Association for the Study of the Liver, Korean Hepatobiliary Surgery
Society, Korean Liver Transplantation Society and Korean Liver Cancer
Society, Jeju Island, Korea
7/2014 Invited Speaker, HCV Symposium, WHO (China)-Chinese Medical
Society-Chinese Society of Hepatology, Beijing, China
9/2014 Invited Speaker, Special Conference on HBV, EASL-APASL Symposium,
Athens, Greece
12/2014 Invited Speaker, APASL Single Topic Conference on Hepatitis B,
Guangzhou, China
3/2015 Moderator and Invited Speaker, APASL Annual Meeting, Istanbul, Turkey
3/2015 Invited Speaker, Hepatology Symposium, Bogota, Colombia
6/2015 Invited Speaker, State of the art lecture, Global Summit on Viral Hepatitis,
Berlin, Germany
7/2015 Co-organizer and invited speaker, Inaugural meeting on Highlights of
2014 AASLD Meeting, sponsored by Chinese Society of Hepatology and
endorsed by AASLD, Beijing and Shanghai, China
9/2015 Moderator, Symposium on Therapy in Liver Diseases, Barcelona, Spain
10/2015 Invited Speaker, AGA-Hangzhou Joint GI meeting, China
2/2016 Invited Speaker and Moderator, APASL Annual Meeting, Tokyo, Japan
4/2016 Invited Speaker and Moderator, EASL International Liver Congress,
Barcelona, Spain
5/2016 Moderator, ANRS Symposium on HBV Cure, Paris, France
6/2016 Invited Speaker and Moderator, APASL Single Topic Conference on
Hepatitis C, Kaohsiung, Taiwan
6/2016 Co-organizer, speaker and moderator, AASLD-Chinese Society of
Hepatology Conference on AASLD meeting highlights, Beijing, China
6/2016 Invited Speaker, Annual Meeting of the Mexican Society of Hepatology,
VeraCruz, Mexico
Anna Suk-Fong Lok 12/5/2016 22
9/2016 Invited Speaker, Biennial Meeting, Latin American Society of Hepatology
(ALEH), Santiago, Chile
12/2016 Invited Speaker, APASL Single Topic Conference on HBV, State of the
art lecture, Beijing, China
Bibliography
Peer-Reviewed Publications
1. Lee PK, Lai CL, Lok ASF, Tse TF, Lai KN, Chow SF and Lam KC. Haemodynamic
responses to intravenous cimetidine in subjects with normal lung function and in subjects
with chronic airway obstruction. Brit J Clin Pharmacol 11:339-343, 1981. PMCID:
PMC1401670/
2. Lai CL, Ng RP and Lok ASF. The diagnostic value of the ratio of serum gamma
glutamyl transpeptidase to alkaline phosphatase in alcoholic liver disease. Scand J
Gastroent 17: 41-47, 1982.
3. Reshef R, Lok ASF and Sherlock S. Cholestatic jaundice in fascioliasis treated with
niclofolan. Brit Med J 285:1243-4, 1982. PMCID: PMC1499778.
4. Wu PC, Lai CL, Lok ASF and Lin HJ. An ultrastructural analysis of hepatocellular
carcinoma. Cancer 2:504-507, 1983.
5. Weller IVD, Karayiannis P, Lok ASF, Montano L, Bamber M, Thomas HC and Sherlock
S. The significance of delta agent infection in chronic hepatitis B virus infection in Great
Britain. Gut 24:1061-3, 1983. PMCID: PMC1420126.
6. Lok ASF, Weller IVD, Karayiannis P, Brown D, Fowler MJF, Monjardino J, Thomas HC
and Sherlock S. Thrice weekly lymphoblastoid interferon is effective in inhibiting
hepatitis B virus replication. Liver 4:45-49, 1984.
7. Fowler MJF, Monjardino J, Weller IVD, Lok ASF and Thomas HC. An analysis of the
molecular state of HBV-DNA in the liver and serum of patients with chronic hepatitis and
primary liver cell cancer and the effect of treatment with adenine arabinoside. Gut
25:611-18, 1984. PMCID: PMC1432367.
8. Lok ASF, Farci P and Thomas HC. Epidemiology and clinical course of delta infection
in Britain. In Delta Infection and Viral Hepatitis, ed Verme G, Bonino F and Rizzetto M,
Alan R Liss, Inc.; pp 219-24.
Anna Suk-Fong Lok 12/5/2016 23
9. Lok ASF, Wilson LA and Thomas HC. Neurotoxicity associated with adenine
arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J
Antimicrob Chemother 14:93-9, 1984.
10. Novick DM, Lok ASF and Thomas HC. Diminished responsiveness of homosexual men
to antiviral therapy in HBsAg positive chronic liver disease. J Hepatol 1:29-35, 1984.
11. Lok ASF, Hadziyannis SJ, Weller IVD, Karvountzis MG, Karayiannis P, Monjardino J,
Montano L and Thomas HC. The contribution of low level HBV replication to
continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B
virus infection. Gut 25:1283-7, 1984. PMC1432328
12. Lai CL, Wu PC, Wong KL and Lok ASF. Clinical features of ulcerative proctocolitis in
Hong Kong Chinese: a review of three decades. Am J Proctology, Gastroenterology,
Colon and Rectal Surgery 36:14-9, 1985.
13. Karayiannis P, Goodall AH, Waters JA, Galpin S, Lok ASF, Thorp R and Thomas HC.
Clinical Evaluation of a monoclonal assay for hepatitis B surface antigen: identification
of “HBsAg-like” polypeptides non reactive in conventional radioimmunoassays. J Med
Virol 15:291-303, 1985.
14. Karayiannis P, Fowler MJF, Lok ASF, Greenfield C, Monjardino J and Thomas HC.
Detection of serum HBV-DNA by molecular hybridization: correlation with HBeAg/anti-
HBe status, racial origin and liver histology. J Hepatol 1:99-106, 1985.
15. Dunk AA, Scott SC, Johnson PJ, Melia W, Lok ASF, Murray Lyon I, Williams R and
Thomas HC. Mitozantrone as a single agent therapy in hepatocellular carcinoma. A
Phase III Study. J Hepatol 1:395-404, 1985.
16. Lok ASF, Lindsay I, Scheuer PH and Thomas HC. Clinical and histological features of
delta infection in chronic hepatitis B virus carriers. J Clin Pathol 38:530-3, 1985.
PMC499203
17. Weller IVD, Lok ASF, Mindel A, Karayiannis P, Galpin S, Monjardino J, Sherlock S and
Thomas HC. A randomized, controlled trial of adenine arabinoside 5'-monophosphate in
chronic hepatitis B virus infection. Gut 26:745-51, 1985. PMC1433015.
18. Karayiannis P, Novick DM, Lok ASF, Fowler MJF, Monjardino J, Thomas HC. Hepatitis
B virus DNA in saliva, urine and seminal fluid of carriers of hepatitis B e antigen. Br
Anna Suk-Fong Lok 12/5/2016 24
Med J 290: 1853-5, 1985. PMC1416807.
19. Lok ASF, van Leeuwen DJ, Thomas HC and Sherlock S. Psychosocial impact of chronic
infection with hepatitis B virus on British patients. Genitourin Med 61:279-82, 1985.
PMC1011831.
20. Lok ASF, Karayiannis P, Jowett TP, Fowler MJF, Farci P, Monjardino J and Thomas HC.
Studies of HBV replication during acute hepatitis followed by recovery and acute
hepatitis progressing to chronic disease. J Hepatol 1:671-9, 1985.
21. Wong KL, Lai CL, Wu PC, Hui WM, Wong KP and Lok ASF. Ultrasonic Studies in
Hepatic Neoplasm: patterns and comparisons with contrast radiological studies. Clin
Radiology 36:511-5, 1985.
22. Lam SK, Lau WY, Lai CL, Lee NW, Poon GP, Hui WM, Lok ASF, Ng MMT, Fok KH,
Yu HC. Efficacy of sucralfate in corpus, prepyloric, and duodenal ulcer - associated
gastric ulcers: a double-blind, placebo controlled study. Am J Med 79 (2C):24-31, 1985.
23. Lok ASF, Novick DM, Karayiannis P, Dunk AA, Sherlock S and Thomas HC. A
randomized study of the effects of adenine arabinoside 5'-monophosphate (short or long
courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology
5:1132-8, 1985.
24. Lam SK, Lau WY, Choi TK, Lai CL, Lok ASF, Hui WM, Ng MMT, Choi SKY.
Prostaglandin E1 (Misoprostol) overcomes the adverse effect of chronic cigarette
smoking on duodenal ulcer healing. Dig Dis Sci 31: 68S-74S, 1986.
25. Fowler MJF, Greenfield C, Chu CM, Karayiannis P, Dunk A, Lok ASF, Lai CL, Teo EK,
Monjardino JP, Wankya BM, Thomas HC. Integration of HBV-DNA may not be a pre-
requisite for the maintenance of the state of malignant transformation - An analysis of
110 liver biopsies. J Hepatol 2:218-29, 1986.
26. Lok ASF, Lai CL, Wong KL and Lam WK. Intrahepatic cholestasis associated with
enlarged gallbladder. Med J Aust 145:36-7, 1986.
27. Lok ASF, Lai CL, Wu PC, Ng MMT. Response to Hepatitis B Vaccine in Family
Members of HBsAg Carriers. J Med Virol 19:33-9, 1986.
28. Lok ASF, Lin HJ, Wu PC, Lai CL. Serum bile acids and other liver function tests in
patients with chronic hepatitis B treated with interferon: an interim report. Proceedings
Anna Suk-Fong Lok 12/5/2016 25
from the Second International Symposium on Bile Acids in Hepatobiliary and
Gastrointestinal Diseases. IRL Press, Oxford pp 85-9, 1986.
29. Lok ASF, Wong KP, Lee PK, Chiu KW, Mok CK, Lam SK. Radiological Diagnosis of
Leiomyosarcoma of the Inferior Vena Cava. Clin Radiol 37:403-5, 1986.
30. Hui WM, Lam SK, Lok ASF, Ng MMT, Wong KL, Fok KH. Sulpiride improves
functional dyspepsia - a double blind, controlled study. J Gastroenterol Hepatol 1:391-
400, 1986.
31. Hui WM, Lam SK, Ho J, Ng MMT, Lui I, Lai CL, Lok ASF, Lau WY, Poon GP, Choi S,
Choi TK. Chronic antral gastritis in duodenal ulcer-natural history and treatment with
prostaglandin E. Gastroenterol 91:1095-101, 1986.
32. Novick DM, Brown DJC, Lok ASF, Lloyd C, Thomas HC. Influence of sexual
preference and chronic hepatitis B virus infection on T lymphocyte subsets, natural killer
activity and suppressor cell activity. J Hepatol 3:371-7, 1986.
33. Lok ASF, Lai CL, Wu PC. Interferon therapy of chronic hepatitis B virus infection in
Chinese. J Hepatol Vol 3 (Suppl 2): S209-S215, 1986.
34. Lok ASF, Lai CL, Wu PC, Leung EKY, Lam TS. Spontaneous Hepatitis B e Antigen to
Antibody Seroconversion and Reversion in Chinese Patients with Chronic Hepatitis B
Virus Infection. Gastroenterol 92:1839-43, 1987.
35. Lok ASF, Lai CL, Hui WM, Ng MT, Wu PC, Lam SK, Leung EKY. Absence of
transmission of hepatitis B by fibreoptic upper gastrointestinal endoscopy. J
Gastroenterol Hepatol 2:175-80, 1987.
36. Lam SK, Hui WM, Lau WY, Branicki FJ, Lai CL, Lok ASF, Ng MMT, Fok PJ, Poon GP,
Choi TK. Cigarette smoking affects healing and relapse of cimetidine treated but not
sucralfate - treated duodenal ulcer. Gastroenterol 19:1193-1201, 1987.
37. Woo E, Chan YF, Lam K, Lok ASF, Yu YL, Huang CY. Apoplectic intracerebral
hemorrhage: an unusual complication of cerebral radiation necrosis. Pathology 19:95-8,
1987.
38. Hui WM, Lam SK, Chau PY, Ho J, Lau WY, Poon KP, Lai CL, Lok ASF, Lui IOL, Ng
MMT. Pathogenetic role of campylobacter pyloridis in gastric ulcer. J Gastroenterol
Hepatol 2:309-16, 1987.
Anna Suk-Fong Lok 12/5/2016 26
39. Lok ASF, Lai CL, Wu PC, Wong VCW, Yeoh EK, Lin HJ. Hepatitis B Virus Infection
in Chinese Families in Hong Kong. Am J Epidemiol 126:492-9. 1987.
40. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. The effect of recombinant
alpha2-interferon in Chinese HBsAg carrier children: a prospective controlled trial.
Lancet 2:877-80, 1987.
41. Lai CL, Gregory PB, Wu PC, Lok ASF, Wong KP, Ng MMT. Hepatocellular carcinoma
in Chinese males and females: possible causes for the male predominance. Cancer
60:1107-11, 1987.
42. Lok ASF, Lai CL, Wu PC. A randomized, controlled trial of recombinant alpha-2
interferon in Chinese patients with chronic hepatitis B virus infection: an interim report.
In Viral Hepatitis and Liver Disease, ed. AJ Zuckerman, Alan R Liss Inc., New York pp
848-9, 1988.
43. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK and Yeung CY. Effect of recombinant
alpha 2-interferon in Chinese Hepatitis B Surface Antigen Carrier Children: A
prospective, controlled trial. In Viral Hepatitis and Liver Disease ed. AJ Zuckerman,
Alan R Liss Inc., New York pp 850.
44. Lok ASF, Lai CL. Factors determining the development of hepatocellular carcinoma
(HCC) in hepatitis B surface antigen carriers: a comparison between families with
clusters and solitary cases of HCC. Cancer 61:1287-91, 1988.
45. Lok ASF, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in
an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination
programs. Hepatology 8:766-70, 1988.
46. Lai CL, Wu PC, Chan GCB, Lok ASF, Lin HJ. Doxorubicin vs no antitumor therapy in
inoperable hepatocellular carcinoma: a prospective, randomized trial. Cancer 62:479-83,
1988.
47. Lok ASF, Ng IOL. Prochlorperazine induced chronic cholestasis. J Hepatol 6:369-373,
1988.
48. Hui WM, Lam SK, Chau PY, Ho J, Lui I, Lai CL, Lok ASF, Ng MMT. Persistence of
Campylobacter pyloridis despite healing of duodenal ulcer and improvement of
accompanying duodenitis and gastritis. Dig Dis Sci 32:1255-60, 1987.
Anna Suk-Fong Lok 12/5/2016 27
49. Lok ASF, Lai CL, Wu PC. A longitudinal follow-up of asymptomatic hepatitis B surface
antigen positive Chinese children. Hepatology 8:1130-3, 1988.
50. Lok ASF, Lai CL, Wu PC, Leung EKY. Long-term follow-up in a randomized,
controlled trial of recombinant alpha-2 interferon in Chinese patients with chronic
hepatitis B infection. Lancet 2:298-302, 1988.
51. Lok ASF, Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic
hepatitis B infection: role in the early detection of hepatocellular carcinoma. Hepatology
9:110-5, 1989.
52. Chung HT, Lai CL, Wu PC and Lok ASF. Synergism of chronic alcoholism and hepatitis
B infection in liver disease. J Gastroenterol Hepatol 4:11-6, 1988.
53. Lok ASF, Lai CL, Wu PC. Response to hepatitis B vaccine in subjects positive for anti
HBc. In Asian symposium on strategies for large scale hepatitis B immunization, ed el
Gouli, Science Press (Hong Kong) pp 141-6, 1988.
54. Branicki FJ, Boey J, Fok PJ, Pritchett CJ, Fan ST, Lai ECS, Mok FPT, Wong WS, Lam
SK, Hui WM, Ng MMT, Lok ASF, Lam DKH, Tang APK, Coleman SY, Wong J.
Bleeding gastric ulcer: a prospective evaluation of rebleeding and mortality. Aust and N
Zealand J Surg 59:551-62, 1988.
55. Hui WM, Lam SK, Ho J, Ng I, Lam WY, Branicki FJ, Lai CL, Lok ASF, Ng MMT, Fok
PJ, Poon GP, Choi TK. The effect of sucralfate and cimetidine on duodenal ulcer
associated antral gastritis and Campylobacter pylori. Am J Med 86: (Suppl 6A) : 60-5,
1989.
56. Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. Fatal
reactivation of chronic hepatitis B virus infection following chemotherapy withdrawal in
lymphoma patients. Quart J Med 73:911-7, 1989.
57. Lok ASF, Lai CL. Acute exacerbation in Chinese patients with chronic hepatitis B virus
infection: incidence, etiology and predisposing factors. J Hepatol 10:29-34, 1990.
58. Wong KF, Yuen RWS, Lok ASF, Chan TK. Granulocytic sarcoma presenting as
bleeding gastric polyp. Pathology 21:63-4, 1989.
59. Lai CL, Wu PC, Lok ASF, Lin HJ, Ngan H, Lau JYN, Chung HT, Ng MMT, Yeoh EK,
Anna Suk-Fong Lok 12/5/2016 28
Arnold M. Recombinant alpha2 interferon is superior to doxorubicin for inoperable
hepatocellular carcinoma: a prospective, randomized trial. Br J Cancer 60:928-33, 1989.
PMC2247256
60. Hui WM, Lam SK, Lau WY, Branicki FJ, Lok ASF, Ng MMT, Lai CL, Poon GP.
Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a
randomized, double-blind study with weekly endoscopic assessment. J Gastroenterol
Hepatol 4 (Suppl 2):35-44, 1989.
61. Lam SK, Hui WM, Ng MMT, Lok ASF, Lai CL, Branicki FJ, Lau WY, Poon GP.
Reducing meal-stimulated acid secretion achieves faster healing of duodenal ulcer than
reducing nocturnal acid secretion. Dig Dis Sci 34:1494-500, 1989.
62. Branicki FJ, Boey J, Fok PJ, Pritchett CJ, Fan ST, Lai ECS, Mok FPT, Wong WS, Lam
SK, Hui WM, Ng MMT, Lok ASF, Lam DKH, Tse MCK, Tang APK, Wong J. Bleeding
duodenal ulcer: a prospective evaluation of risk factors for rebleeding and death. Ann
Surg 211:411-8, 1990.
63. Lai ECS, Ng IOL, Ng MMT, Lok ASF, Tam PC, Fan ST, Choi TK, Wong J. Long-term
results of resection for large hepatocellular carcinoma: a multivariate analysis of clinico-
pathological features. Hepatology 11:815-8, 1990.
64. Lok ASF, Lai CL, Leung EKY. Interferon antibodies may negate the antiviral effects of
recombinant alpha-interferon treatment in patients with chronic hepatitis B virus
infection. Hepatology 12:1266-70, 1990.
65. Lok ASF, Ma OCK. Hepatitis B virus replication in Chinese patients with hepatocellular
carcinoma. Hepatology 12:582-8, 1990.
66. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of
hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterol
100:182-8, 1991.
67. Lok ASF, Lai CL. Incidence, neutralizing activity and clinical significance of interferon
antibodies in chronic hepatitis B patients receiving recombinant alpha interferons. In
Viral Hepatitis and Liver Disease, ed. Hollinger FB, Lemon SM, Margolis HS, Williams
and Wilkins, Baltimore, 643-5, 1991.
68. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd D, Chiu EKW. Hepatitis B infection in
patients with lymphomas. Hemat Oncol 8:261-70, 1990.
Anna Suk-Fong Lok 12/5/2016 29
69. Lai CL, Lau JYN, Lin HJ, Lok ASF, Wu PC, Chung HT, Wong LSK, Leung MP, Yeung
CY. Effect of recombinant alpha2 interferon with or without prednisone in Chinese
HBsAg carrier children: a prospective, double-blind, controlled trial. Quart J Med
286:155-63, 1991.
70. Lok ASF, Ma OCK, Lau JYN. Alpha-interferon therapy in patients with chronic hepatitis
B virus infection: effects on hepatitis B virus deoxyribonucleic acid in the liver.
Gastroenterol 100:756-61, 1991.
71. Lok ASF, Lai CL, Chung HT, Lau JYN, Leung EKY, Wong LSK. Morbidity and
mortality from chronic hepatitis B virus infection in family members of patients with
malignant and non-malignant hepatitis B virus related chronic liver diseases. Hepatology
13:834-7, 1991.
72. Hui WM, Lam SK, Ho J, Lai CL, Lok ASF, Ng MMT, Lau WY, Branicki FJ. The effect
of omeprazole on duodenal ulcer-associated antral gastritis and helicobacter pylori. Dig
Dis Sci 36:577-82, 1991.
73. Chin KP, Lok ASF, Wong LSK, Lai CL, Wu PC. Current seroepidemiology of hepatitis
A in Hong Kong. J Med Virol 34:191-3, 1991.
74. Lau JYN, Lai CL, Wu PC, Chung HT, Lok ASF, Lin HJ. Randomized, controlled trial of
recombinant interferon-gamma in chronic hepatitis B virus infection. J Med Virol
34:184-7, 1991.
75. Chan TM, Lok ASF, Cheng IKP. Hepatitis C in renal transplant recipients.
Transplantation 52:810-3, 1991.
76. Hui WM, Ng MMT, Lok ASF, Lai CL, Lau YN, Lam SK. A randomized, prospective
study of the efficacy of laser, heater probe and bipolar electrocoagulation in acute
bleeding ulcer. Gastrointest Endosc 37:299-304, 1991.
77. Chan TM, Lok ASF, Cheng IKP. Hepatitis C infection among dialysis patients: a
comparison between patients on maintenance haemodialysis and continuous ambulatory
peritoneal dialysis. Nephrol Dial Transp 6:944-7, 1991.
78. Lok ASF, Ma OCK, Chan TM, Lai CL, Chung HT, Ng CPL, Lam JSC. Over estimation
of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera.
Hepatology 14:756-62, 1991.
Anna Suk-Fong Lok 12/5/2016 30
79. Lok ASF, Wong, A, Sporton S, Lai CL, Liu V, Chung HT. Hepatitis D virus
superinfection remains a rare occurrence in non-drug abusers in Hong Kong. J Hepatol
14:332-4, 1992.
80. Thomas HC, Dusheiko GM, Farrell G, Cooksley WEF, Lok ASF, Perez V, Tanno H,
Carreno V, Ryff JC. Comparative study of three doses of interferon alpha-2a in chronic
active hepatitis B ed Hollinger FB, Lemon SM, Margolis HS, Williams and Wilkins,
Baltimore, 641-2, 1991.
81. Carman WF, Ferrao M, Lok ASF, Ma OCK, Lai CL, Thomas HC. Pre-core sequence
variation in Chinese isolates of hepatitis B virus: relationship to HBe status and activity
of liver disease. J Infect Dis 165:127-33, 1992.
82. Chan PCK, Lok ASF, Cheng IKP, Chan MK. The impact of donor and recipient hepatitis
B surface antigen status on liver disease and survival in renal transplant recipients.
Transplantation 53:128-31, 1992.
83. Hui WM, Lam SK, Lok ASF, Ng MMT, Lai CL. Maintenance therapy for duodenal
ulcer: A randomized controlled comparison of seven forms of treatment. Am J Med
92:265-74, 1992.
84. Lok ASF, Wu PC, Lai CL, Lau JYN, Leung EKY, Wong LSK, Ma OCK, Lauder IJ, Ng
CPL, Chung HT. A controlled trial of interferon with or without prednisone priming for
chronic hepatitis B. Gastroenterol 102:2091-7, 1992.
85. Lok ASF, Cheung R, Chan R, Liu V. Hepatitis C viremia in patients with hepatitis C
virus infection. Hepatology 15:1007-12, 1992.
86. Wu PC, Lok ASF, Lau JYN, Lauder IJ, Lai CL. Histologic changes in Chinese patients
with chronic hepatitis B virus infection following interferon - alpha therapy. Am J Clin
Pathol 98: 402-7, 1992.
87. Wong SN, Yu ECL, Lok ASF, Chan KW, Lau YL. Interferon treatment for hepatitis B
associated membranous glomerulonephritis in two Chinese children. Paed Nephrol
6:417-20, 1992.
88. Cheung R, Lok ASF. Correlation between HCV viremia and spontaneous or interferon
induced remissions in chronic hepatitis C. Proc 3rd Int'l Symposium on HCV,
Strasbourg, 1991.
Anna Suk-Fong Lok 12/5/2016 31
89. Chung HT, Lok ASF, Lai CL. Re-evaluation of interferon treatment of chronic hepatitis
B using polymerase chain reaction. J Hepatol 17:208-14, 1993.
90. Chan TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus (HCV)
infection in hemodialysis patients: a longitudinal study comparing the results of HCV
RNA and anti-HCV assays. Hepatology 17:5-8, 1993.
91. Cheng IKP, Chan DTM, Lok ASF. Hepatitis C infection among renal transplant
recipients: a comparative study using first and second generation anti-HCV EIA and HCV
detection by nested PCR. Trans Proc 25:1460-2, 1993.
92. Lok ASF, Kwan WK, Moeckli R, Yarbough PO, Chan RT, Reyes GR, Lai CL, Chung
HT, Lai TST. A seroepidemiological survey of hepatitis E in Hong Kong using
recombinant based enzyme immunoassays. Lancet 2:1205-9, 1992.
93. Chan TM, Lok ASF, Cheng IKP, Chan RT. A prospective study on hepatitis C virus
infection among renal transplant recipients. Gastroenterol 104:862-8, 1993.
94. Terris B, Machio A, Mattei MG, Fagan E, Lok A, Tiollais P, Dejean A. Abnormal
expression of hepatitis B virus sequences integrated in human hepatocellular carcinomas.
Gastroenterologie Clinique Biologique 16:511-7, 1992.
95. Hui WM, Shiu LP, Lok AS, Lam SK. Life events and daily hassles in duodenal ulcer
disease. A prospective study of patients with active disease and in remission. Digestion
52:165-72, 1992.
96. Cheung RC, Chan RT, Lok ASF. Longitudinal study of hepatitis C viremia in chronic
hepatitis C. J Med Virol 41:338-42, 1993.
97. Chan TM, Lok ASF, Cheng IKP, Ng IOL, Chan KW. Chronic hepatitis C after renal
transplantation: treatment with alpha interferon. Transplantation 56:1095-8, 1993.
98. Lok ASF, Chien D, Choo QL, Chan TM, Chiu EKW, Cheng IKP, Houghton M, Kuo G.
Antibody response to core, envelope and non-structural hepatitis C virus antigens:
comparison between immunocompetent and immunosuppressed patients. Hepatology
18:497-502, 1993.
99. Chung HT, Lee JSK, Lok ASF. Prevention of post-transfusion hepatitis B and C by
screening for antibody to hepatitis C virus and antibody to hepatitis B core antigen.
Anna Suk-Fong Lok 12/5/2016 32
Hepatology 18:1045-9, 1993.
100. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B
patients treated with alpha interferon. Gastroenterol 105:1833-8, 1993.
101. Lok ASF, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus
serve to enhance the stability of the secondary structure of the pregenome encapsidation
signal. Proc Natl Acad Sci USA 91:4077-81, 1994. PMC43726
102. Akarca US, Greene S, Lok ASF. Detection of pre-core hepatitis B virus mutants in
asymptomatic hepatitis B surface antigen positive family members. Hepatology 19:1366-
70, 1994.
103. Crowe JS, Gewert DR, Barber KA, Lewis AP, Sims MJ, Davies SL, Salom CL, Wood J,
Thomas HC, Thursz M, Lok AS. Interferon alpha-2 genotype analysis of Chinese chronic
hepatitis B patients undergoing recombinant interferon-alpha 2a therapy. J Infect Dis
169:875-8, 1994.
104. Lok ASF, Akarca US, Greene S. Predictive value of pre-core hepatitis B virus mutations
in spontaneous and interferon induced hepatitis B e antigen clearance. Hepatology 21:19-
24, 1995.
105. Chan TM, Wu PC, Lau JYN, Lai CL, Lok ASF, Cheng IKP. Clinicopathologic features
of hepatitis C virus infection in renal allograft recipients. Transplantation 58:996-1000,
1994.
106. Thomas HC, Lok ASF, Carreno V, Farrell G, Tanno H, Perez V, Dusheiko GM, Cooksley
G, Ryff JC and the International Hepatitis Trial Group. Comparative Study of three doses
of interferon -2a in chronic active hepatitis B. J Viral Hep 1:139-148, 1994.
107. Chung HT, Lai CL, Lok ASF. Pathogenic role of hepatitis B virus in hepatitis B surface
antigen negative decompensated cirrhosis. Hepatology 22:25-29, 1995.
108. Akarca US and Lok ASF. Naturally occurring hepatitis B virus core gene mutations.
Hepatology 22:50-60,1995.
109. Akarca US and Lok ASF. Naturally occurring core gene defective hepatitis B viruses. J
Gen Virol 76:1821-6, 1995.
110. Ghany MG, Leissinger C. Lagier R, Sanchez-Pescador R, Lok ASF. Effect of human
Anna Suk-Fong Lok 12/5/2016 33
immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis
Sci 41:1265-72, 1996.
111. Zhang YY, Lok ASF, Chan DTM, Widell A. Greater diversity of hepatitis C virus
genotypes found in Hong Kong than in mainland China. J. Clin Microbiol 33:2931-4,
1995. PMC228609
112. Bozkaya H, Ayola B, Lok ASF. High rate of mutations in the hepatitis B core gene
during the immune clearance phase of chronic hepatitis B virus infection. Hepatology
24:32-37, 1996.
113. Haque S, Chandra B, Gerber MA, Lok ASF. Iron overload in patients with chronic
hepatitis C: a clinicopathologic study. Human Pathol 27:1277-81, 1996.
114. Ghany MG, Chan TM, Sanchez-Pescador R, Urdea M, Lok ASF. Correlation between
serum HCV RNA and aminotransferase levels in patients with chronic HCV infection.
Dig Dis Sci 41:2213-8, 1996.
115. Bozkaya H, Akarca US, Ayola B, Lok ASF. High degree of conservation in the hepatitis
B virus core gene during the immune tolerant phase in perinatally acquired chronic
hepatitis B virus infection. J Hepatol 26:508-516, 1997.
116. Lau GKK, Lok ASF, Liang RHS, Lai CL, Chiu EKW, Lau YL, Lam SK. Clearance of
HBsAg after bone marrow transplantation: role of adoptive immunity transfer.
Hepatology 25:1497-1501, 1997
117. Shehab TM, Kaminski MS, Lok ASF. Acute liver failure due to hepatic involvement by
hematologic malignancy. Dig Dis Sci 42:1400-5, 1997.
118. Chan TM, Wu PC, Lau JYN, Lok ASF, Lai CL, Cheng IKP. Interferon treatment for
hepatitis C virus infection in patients on hemodialysis. Nephrol Dial Transplant 12:1414-
9, 1997.
119. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. Hepatitis
B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B
immune globulin prophylaxis. Hepatology 27:213-222, 1998.
120. Lok ASF, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and
hepatitis B virus DNA levels in response to interferon therapy for chronic hepatitis B. J
Viral Hep 5:171-178, 1998.
Anna Suk-Fong Lok 12/5/2016 34
121. Chan TM, Lau JYN, Wu PC, Lai CL, Lok ASF, Cheng IKP. Hepatitis C virus genotypes
in patients on renal replacement therapy. Nephrol Dial Transplant 13:731-4, 1998.
122. Chan HLY, Hussain M, Lok ASF. Different hepatitis B virus genotypes are associated
with different mutations in the core promoter and precore regions during HBeAg
seroconversion. Hepatology 29:976-984, 1999.
123. Shehab TM, Sonnad SS, Jefferies M, Gunaratnam N, Lok ASF. Current practice patterns
of primary care physicians in the management of patients with hepatitis C. Hepatology
30: 794-800, 1999.
124. Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen
negative chronic hepatitis B in Hong Kong. Hepatology 31:763-768, 2000.
125. Lok ASF, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi
M, Andreone P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e
antigen negative patients receiving lamivudine therapy. Hepatology 32:1145-1153, 2000.
126. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF
and the HEP DART International Committee. Nomenclature for antiviral resistant human
hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757, 2001.
127. Fontana RJ, Moyer CA, Sonnad SS, Lok ASF, Sneed-Pee N, Walsh J, Klein S, Webster
S. Co-morbidities and quality of life in patients with interferon refractory chronic
hepatitis C. Am J Gastroenterol 96:170-178, 2001.
128. Teo EK, Ostapowicz G, Hussain M, Lee WM. Fontana RJ, Lok ASF. Hepatitis B
infection in patients with acute liver failure in the United States. Hepatology 33:972-976,
2001.
129. Shehab, TM, Sonnad SS, Lok ASF. Management of hepatitis C patients by primary care
physicians in the United States: results of a national survey. J Viral Hepatitis 8:377-383,
2001.
130. Teo EK, Han SH, Terrault, N. Luketic V, Jensen D, Keeffe EB, Lok ASF and the HBV-
OLT Study Group. Liver transplantation in patients with hepatitis B virus infection:
outcome in Asians versus Whites. Hepatology 34:126-132, 2001.
131. Funk ML, Rosenberg DM, Lok AS. Worldwide epidemiology of HBeAg-negative
Anna Suk-Fong Lok 12/5/2016 35
chronic hepatitis B (e-CHB) and associated precore and core promoter variants. J Viral
Hepatitis 9:52-61,2002.
132. Hussain KB, Fontana RJ, Moyer CA, Su GL, Sneed-Pee N, Lok ASF. Co-morbid illness
is an important determinant of health related quality of life in patients with chronic
hepatitis C. Am J Gastroenterol 96:2737-2744, 2001.
133. Fontana RJ, Hussain KB, Schwartz S, Moyer C, Su G, Lok ASF. Emotional distress in
hepatitis C patients not receiving antiviral therapy. J Hepatol 36:401-7, 2002.
134. Chu CJ, Fontana RJ, Moore C, Armstrong DR, Punch JD, Su GL, Magee JC, Merion
RM, Lok ASF. Outcome of liver transplantation for hepatitis B: report of a single center's
experience. Liver Transpl 7:724-731,2001.
135. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier
HBeAg seroconversion compared to hepatitis B virus genotype C. Gastroenterol
122:1756-1762, 2002.
136. Fontana RJ, Schwartz SM, Gebremariam A, Lok ASF, Moyer CA. Emotional distress
during interferon 2b and ribavirin treatment of chronic hepatitis C. Psychosomatics
43:378-385, 2002.
137. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley, Soldevila-Pico C,
McClure LA, Lok ASF for the NIH HBV-OLT study group. Effect of Lamivudine
treatment on survival of 309 North America patients awaiting liver transplantation for
chronic hepatitis B. Liver Transpl 8:433-439, 2002.
138. Fontana RJ, Walsh J, Moyer CA, Lok AS, Webster S, Klein S. High-dose interferon alfa-
2b and ribavirin in patients previously treated with interferon: results of a prospective,
randomized, controlled trial. J Clin Gastroenterol 34(2):177-82, 2002
139. Shehab TM, Orrego M, Chunduri R, Lok ASF. Identification and management of
Hepatitis C patients in primary care clinics. Am J Gastroenterol 98:639-644, 2003.
140. Lok ASF, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G,
Hulstaert F, DeVreese K, Sablon E. Monitoring drug resistance in chronic Hepatitis B
patients during Lamivudine therapy: performance evaluation of INNO-LIPA HBV D R. J
Clin Microbiol 40:3729-34, 2002. PMC130856.
Anna Suk-Fong Lok 12/5/2016 36
141. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick D, Lok AS. NAFLD may be a
common underlying liver disease in patients with hepatocellular carcinoma in the United
States. Hepatology 36:1349-54, 2002.
142. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different
stages of chronic hepatitis B infection. Hepatology 36:1408-15, 2002.
143. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with higher rate of
response to interferon therapy in Chinese patients with HBeAg positive chronic hepatitis
than genotype C. Hepatology 36:1425-30, 2002.
144. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-
gamma carboxyprothrombin can differentiate hepatocellular carcinoma from
nonmalignant chronic liver disease in American patients. Hepatology 37:1114-1121,
2003.
145. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown Jr
RS, Luketic VA, Terrault N, Lok AS. HBV genotypes in the United States: results of a
nationwide study. Gastroenterol 125:444-451, 2003.
146. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown Jr
RS, Luketic VA, Terrault N, Lok AS. Prevalence of HBV precore/core promoter variants
in the United States. Hepatology 38:619-628, 2003.
147. Hussain M, Chu CJ, Sablon E, Lok ASF. Rapid and sensitive assays for the determination
of HBV genotypes and the detection of HBV precore and core promoter variants. J Clin
Microbiol 41:3699-3705, 2003. PMC179815.
148. Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok
AS. A simple non-invasive index can predict both significant fibrosis and cirrhosis in
patients with chronic hepatitis C. Hepatology 38:518-526, 2003.
149. Moyer CA, Fontana RJ, Hussain K, Lok ASF, Schwartz S. The role of
optimism/pessimism in HRQOL in chronic hepatitis C patients. J Clin Psychol in Med
Settings. 10:41-49, 2003.
150. Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ,
Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine
treatment in patients with chronic hepatitis B. Gastroenterol 125:1714-1722, 2003.
Anna Suk-Fong Lok 12/5/2016 37
151. DiBisceglie AM, Lyra AC, Schwarz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain
KB, Gish R, van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J,
Flamm S, Blei A, Befeler AS, and the Liver Cancer Network. Hepatitis C related
hepatocellular carcinoma in the United States: influence of ethnic status. Am J
Gastroenterol 98:2060-3, 2003.
152. Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok ASF. Effectiveness of
interferon-2b and ribavirin therapy in treatment naïve chronic hepatitis C patients in an
academic clinical practice. Clin Gastro and Hepatol 2: 425-431, 2004.
153. Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after a 2-year course of
lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat
11:432-8, 2004.
154. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson ET, Lok
AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD,
Everhart JE and the HALT-C Trial Group. Peginterferon alfa-2a and ribavirin in patients
with chronic hepatitis C who have failed prior treatment. Gastroenterol 126:1015-1023,
2004.
155. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT,
DiBisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE.
Evolution of the HALT-C Trial: Pegylated Interferon as Maintenance Therapy for
Chronic Hepatitis C in Previous Interferon Nonresponders. Controlled Clinical Trials
25:472-492, 2004.
156. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, Tobacco and
Obesity Are Synergistic Risk Factors for Hepatocellular Carcinoma. J Hepatol 42:218-
224, 2005.
157. Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, Davern TJ, Lee WM,
Lok ASF and the US Acute Liver Failure Study Group. Clinical Outcome and virological
characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat
12:192-8, 2005.
158. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the
prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing
liver mass. Liver Transpl 11:281-289, 2005.
159. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS.
Anna Suk-Fong Lok 12/5/2016 38
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American
cohort. Hepatology 41:707-716, 2005.
160. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Herbert L.
Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR,
Ghany MG, Gretch DR and the HALT-C Trial Group. Serum alpha-fetoprotein levels in
patients with advanced hepatitis C: results from the HALT-C trial. J Hepatol 43:434-441,
2005.
161. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok
AS, Conjeevaram HS. One-year intense nutritional counseling results in histological
improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J
Gastroenterol 100:1072-1081, 2005.
162. Lok ASF, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE,
Lindsay KL, Bonkovsky HL, DiBisceglie AM, Lee WM, Morgan TR, Dienstag JL,
Morishima C and the HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis
C based on standard laboratory tests: results in the HALT-C cohort. Hepatology 42:282-
292, 2005.
163. Fung SK, Andreone P, Han SH, K. Reddy R, Regev A, Keeffe EB, Hussain M, Cursaro
C, Richtmyer P, Marrero JA, Lok ASF. Adefovir-resistant Hepatitis B can be Associated
with Viral Rebound and Hepatic Decompensation. J Hepatol 43:937-943, 2005.
164. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA,
Lok AS , D’Amelio A and Timothy M. Block TM. GP73, a resident Golgi glycoprotein,
is a novel serum marker for Hepatocellular Carcinoma. J Hepatol 43:1007-12, 2005.
165. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok AS, Latha
Padmanabhan L, and the HALT-C Trial Group. Cognitive function in Hepatitis C
patients with advanced fibrosis: Results from the HALT-C trial. J Hepatol 43:614-622,
2005. PMC3772520
166. McGuire BM, Bonkovsky HL, Carithers RL, Chung RT, Goldstein LI, Lake JR, Lok AS,
Potter CJ, Rand E, Voigt MD, Davis PR, Bloomer JR. Liver Transplantation for
Erythropoietic Protoporphyria Liver Disease. Liver Transpl 11:1590-6, 2005.
167. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero JA, Oberhelman K, Hussain
M, Lok AS. Virologic Response and Resistance to Adefovir in Patients with Chronic
Hepatitis B. J Hepatol; 44:283-290, 2006.
168. Bielauskas LA, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok AS,
Padmanabhan L, Fontana RJ and the HALT-C Trial Group. Clinical relevance of
cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol
Anna Suk-Fong Lok 12/5/2016 39
28:1346-1361, 2006.
169. Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, Soldevila-Pico
C, Fried M, Jensen D, Brown RS Jr, Horwith G, Brundage R, Lok A. Protective antibody
levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined
with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
Liver Transpl; 29:124-133, 2006. PMC1393162
170. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok ASF. Sensitive
line probe assay that simultaneously detects mutations conveying resistance to lamivudine
and adefovir. J Clin Microbiol; 44: 1094-7, 2006.
171. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber
R, Zink RC, Cross A, Colonno R, Fernandes L for the AI463027 BEHoLD Study Group.
A randomized, double-blind comparison of entecavir to lamivudine for treatment of
HBeAg-negative chronic hepatitis B in nucleoside-naïve patients. N Engl J Med;
354:1011-1020, 2006.
172. Chang TT, Gish RG, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhy
J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D for the Entecavir BEHoLD
AI463022 Study Group. A randomized, double-blind comparison of entecavir to
lamivudine for treatment of HBeAg-positive chronic hepatitis B in nucleoside-naïve
patients. N Engl J Med; 354:1001-1010, 2006.
173. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay
KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG,
Gretch DR and the HALT-C Trial Group. HCV RNA detection by TMA during the
hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology;
44:360-7, 2006.
174. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok ASF. Evolution of multi-drug
resistant hepatitis B virus during sequential therapy: implications on rescue therapy.
Hepatology; 44: 703-712, 2006.
175. Fung SK, Wong FSH, Wong DKH, Hussain MT, Lok ASF. Hepatitis B virus genotypes,
precore and core promoter variants among predominantly Asian patients with chronic
HBV infection in a Canadian center. Liver Int 26:796-804, 2006.
176. Wong SN, Reddy KR, Keeffe EB, Han SH, Gaglio PJ, Perrillo RP, Tran TT, Pruett TL,
Lok ASF and the NIH HBV-OLT Study Group. Comparison of clinical outcomes in
Anna Suk-Fong Lok 12/5/2016 40
chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma.
Liver Transpl 13:334-342, 2007.
177. Lok ASF, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson
GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM. Lee WT, Morgan TR, Ghany MG,
Morishima C and the HALT-C Trial Group. Hepatic Steatosis in Hepatitis C: Comparison
of Diabetic and non-diabetic Patients in the Hepatitis C Antiviral Long-Term Treatment
against Cirrhosis Trial. Clin Gastro Hepatol 5:245-254, 2007.
178. Terrault NA, Shiffman ML, Lok ASF, Saab S, Tong L, Brown RS, Everson GT, Reddy R,
Fair JH, Kulik LM, Pruett TL, Seeff LB and the A2ALL Study Group. Outcomes in
hepatitis C virus infected recipients of living donor versus deceased donor liver
transplantation. Liver Transpl; 13:122-9, 2007. PMC3155862
179. Shiffman ML, Ghany MG, Morgan TR, WrightEC, Everson GT, Lindsay KL, Lok ASF,
Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR, and the HALT-C
Trial Group. Impact of reducing peginterferon alfa-2a and ribavirin dose on virologic
response in patients with chronic hepatitis C. Gastroenterology 132:103-12, 2007.
180. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn
JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL,
Ghany MG, Morishima C, and
the HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for
chronic hepatitis C: lessons from the HALT-C Trial. Hepatology 44:1675-1684, 2006.
181. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ and Lok ASF. HBV
recurrence is infrequent after withdrawal of long-term hepatitis B immune globulin
(HBIG) in patients receiving maintenance nucleos(t)ide analogue (NA) therapy. Liver
Transpl 13;374-381, 2007.
182. Volk ML, Marrero JA, Lok AS, Ubel PA. Who decides? Living donor liver
transplantation for advanced hepatocellular carcinoma. Transplantation 82: 1136-9, 2006.
183. Liu Y, Hussain M, Wong S, Fung SK, Yim HJ, Lok AS. A genotype-independent real-
time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol 45:553-8,
2007. PMC1829020
184. Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok
ASF, Kronfol Z, Latha Padmanabhan L and the HALT-C Trial Group. Cognitive
function does not worsen during peginterferon and ribavirin treatment of chronic hepatitis
C. Hepatology 45:1154-63, 2007.
Anna Suk-Fong Lok 12/5/2016 41
185. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F,
Sullivan P, and Lok AS. Sustained virologic response to therapy of recurrent hepatitis C
after liver transplantation is related to early virologic response and dose adherence. Liver
Transpl 13:1100-8, 2007.
186. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS and the NIH HBV-OLT Study
Group. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV
recurrence after liver transplant. Liver Transpl 13:1137-44, 2007.
187. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular
carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and
AFP-L3. Cancer Biomarkers 3:79-87, 2007.
188. Fisher RA, Kulik LM, Freise CF, Lok ASF, Shearon TH, Brown RS, Ghobrial RM, Fair
JH, Olthoff KM, Kam I, Berg CL and the A2ALL Study Group. Hepatocellular
carcinoma recurrence and death following living and diseased donor liver transplantation:
the A2ALL Study. Am J Transpl 7:1601-8, 2007. PMC3176596
189. Volk ML, Hernandez JC, Lok AS, Marrero JA. A modified Charlson Comorbidity Index
for predicting survival after liver transplantation. Liver Transpl 13:1515-1520, 2007.
190. Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok AS, Fontana
RJ and the HALT-C Trial Group. Cognitive reserve and neuropsychological functioning
in patients infected with hepatitis C. J Int Neuropsychol Soc 18: 1-6, 2007.
191. Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, Lok ASF and the
NIH HBV-OLT Study Group. Outcomes of patients with hepatitis B who developed
antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol and
Hepatol 5:1454-1461, 2007. PMC2645788
192. Shetty K, Hussain M, Nei L, Reddy KR, Lok ASF. The prevalence and significance of
occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver
Transplantation 14: 534-540, 2008. PMID: 18324677
193. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Han KH, Chao YC, Lee SD,
Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy up to 96 weeks in
patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133: 1437-1444,
2007.
Anna Suk-Fong Lok 12/5/2016 42
194. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky H, Dienstag JL, Shiffman ML,
Lindsay KL, Lok ASF, DiBisceglie AM, Lee WM, Ghany MG and the HALT-C Trial
Group. Use of Herbal Products by Persons Enrolled in the Hepatitis C Antiviral Long-
Term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 47: 605-12, 2008. PMID:
18157835
195. Tan J, Degertekin B, Wong SN, Hussain M, Oberhelman K, Lok ASF. Tenofovir
monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir
in the absence of adefovir-resistant mutations. J Hepatol 48: 391-8, 2008. PMID:
18199519
196. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS,
Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, and the HALT-C Trial Group.
Blunted cytopenias and weight loss: new correlates of virologic null response to re-
treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 6: 234-41, 2008. PMID:
18237873
197. Campsen J, Blei AT, Emond JC, Everhart JE, Freise CE, Lok AS, Saab S, Wisniewski
KA, Trotter J, and the A2ALL Study Group. Outcomes of living donor liver
transplantation for acute liver failure: A2ALL study. Liver Transplantation 14:1273-80,
2008. PMC3732478
198. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman
ML, Verson GT, Lindsay KL, Lee WM, Lok ASF, Dienstag JL, Ghany MG, Curto TM
and the HALT-C Trial Group. Interpretation of positive TMA test results from PCR-
negative samples obtained after treatment of chronic hepatitis C. Hepatology; 48:1412-9,
2008. PMC2804270
199. Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C,
Lok ASF, Stoddard AM, and the HALT-C Trial Group. Changes in Mood States and
Biomarkers during Peginterferon and Ribavirin Treatment of Chronic Hepatitis C. Am J
Gastroenterol 103: 2766-75, 2008. PMC3712502
200. Gaglio P, Singh S, Degertekin, B, Ishitani M, Hussain M, Perrillo R, Lok ASF and the
NIH HBV-OLT Study Group. Impact of HBV genotype on pre- and post- liver
transplantation outcomes. Liver Transplantation 14: 1420-7, 2008. PMID: 18825703
201. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS. Re-weighting the Model for
End-Stage Liver Disease Score Components. Gastroenterology 135:1575-81, 2008.
PMID: 18835388
Anna Suk-Fong Lok 12/5/2016 43
202. DiBisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee
WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK,
Dienstag JL for the HALT-C Trial Group. Prolonged therapy of advanced chronic
hepatitis C with low dose peginterferon. NEJM 359: 2429-41, 2008. PMC2606037.
203. Volk ML, Lok ASF, Pelletier SJ, Ubel PA, Hayward RA. The impact of MELD
allocation policy on utilization of high risk organs for liver transplantation. Gastroenterol
135:1568-74, 2008. PMID: 19009713
204. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT,
Lindsay KL,Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman
ZD, and the HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated
risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136: 138-148,
2009. PMC3749922
205. Friese CE, Gillespie BW, Koffron AJ, Lok ASF, Pruett TL, Emond JC, Fair JH, Olthoff
KM, Trotter JF, Ghobrial RM, Everhart JE and the A2ALL Study Group. Recipient
Morbidity after Living and Deceased Donor Liver Transplantation: Findings from the
A2ALL Retrospective Cohort Study. Am J Transpl 8:2569-79, 2008. PMC 3297482.
206. Volk ML, Lok AS, Ubel PA, Viajn S. Beyond Utilitarianism: a method for analyzing
competing ethical principles in a decision analysis of liver transplantation. Med Decis
Making 28: 763-772, 2008. PMID: 18725405
207. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. Sensitivity and accuracy of an
updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis
B antiviral resistance. J Hepatol 50: 42-8, 2009. PMID: 19019484
208. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL
and the HALT-C Trial Group. Serum fibrosis marker levels decrease after successful
antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin
Gastroenterol Hepatol 7: 219-26, 2009. PMC3766729
209. Lok AS , Everhart JE
, Chung RT
, Kim H
, Everson GT, Hoefs JC, Greenson JK
, Sterling
RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C,
and the HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced
hepatitis C: results from the HALT-C Trial. Hepatology 49: 1828-37, 2009.
PMC2692566.
Anna Suk-Fong Lok 12/5/2016 44
210. Bzowej N, Han S, Degertekin B, Keeffe EB, Emre S, Brown R, Reddy R, Lok AS, and
the NIH HBV OLT Study Group. Liver Transplantation Outcomes among Caucasians,
Asian Americans and African Americans with Hepatitis B. Liver Transpl 28: 1010-20,
2009. PMID: 19718627
211. Ito K, Kim KH, Lok AS, Tong S. Characterization of genotype specific carboxyl terminal
cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the
candidate enzyme. J Virol; 83: 3507-17, 2009. PMC2663268
212. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky H,
Ghany MG and the HALT-C Trial Group. Weight Related Effects on Disease Progression
in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial. Gastroenterol
137: 549-57, 2009. PMCID: 3148692
213. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois
D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S,
Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound
alfafetoprotein in early hepatocellular carcinoma. Gastroenterol 137: 110-8, 2009.
PMC2704256
214. Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS. Renal Outcomes after
Liver Transplantation in the MELD Era. Liver Transpl 28:1142-8, 2009. PMID:19718633
215. Orman ES and Lok AS. Outcomes of Patients with Chest Tube Insertion for Hepatic
Hydrothorax. Hepatol Int 3: 582-6, 2009. PMC2790584
216. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM,
Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC11
MD, Dienstag JL, Morishima C,
Abnet CC, Sinha R, and the HALT-C Trial Group. Coffee Intake Is Associated with
Lower Rates of Liver Disease Progression in Chronic Hepatitis C. Hepatology 50: 1360-
9, 2009. PMC2783828
217. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC,
Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation
for hepatocellular carcinoma using organ procurement transplant network data. Liver
Transpl 29: 859-868, 2009. PMID: 19642139
218. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC,
Naishadham D, Everson GT, Lok AS, DiBisceglie AM, Bonkovsky HL, Ghany MG and
the HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2a
Anna Suk-Fong Lok 12/5/2016 45
maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterol 137: 1986-
94, 2009. PMC3774149
219. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC,
Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR,
Dienstag JL and the HALT-C Trial Group. Predicting clinical and histological outcomes
based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterol 138:
136-146, 2010. PMC2813393.
220. Volk ML, Tocco R, Saini S, Lok AS. The Public Health Impact of Antiviral Therapy for
Hepatitis C in the United States. Hepatology 50: 1750-6, 2009. PMID: 19824079
221. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, DiBisceglie AM, Morgan TR,
Kim HY, Lee WM, Bonkovsky HL, Dienstag JL, and the HALT-C Trial Group. Des--
carboxy prothrombin and -fetoprotein as biomarkers for the early detection of
hepatocellular carcinoma. Gastroenterol 138: 493-502, 2010. PMC2819612.
222. Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS,
Marrero JA. Clinical presentation and prognostic factors for intrahepatic and extrahepatic
cholangiocarcinoma in a tertiary care center. Aliment Pharmacol Ther 31: 625-633, 2010.
PMID: 20003093.
223. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS, Emre, Soldevila-
Pico C, Reddy KR, Ishitani MB , Tran TT, Pruett TL, Lok ASF, and the NIH HBV-OLT
Study Group. Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B
Recurrence after Liver Transplantation. Am J Transpl 10: 1823-33, 2010. PMC2910807
224. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, Kronfol
Z. Cognitive function does not worsen during long-term low-dose peginterferon therapy
in patients with chronic hepatitis C. Am J Gastroenterol 105: 1551-60, 2010.
PMC3772520
226. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M,
Ludwig DA, Lok AS, Chung RT and the HALT-C Trial Group. Reduction of insulin
resistance with effective clearance of hepatitis C infection: results from the HALT-C
Trial. Clin Gastroenterol and Hepatol 8: 458-62, 2010. PMC2856733
227. Lee J, Lok AS, Chen J. Hepatitis B prevalence among Asian Americans in Michigan: an
assessment to guide future education and intervention strategies. J Community Health 35:
534-42, 2010. PMID: 20300810.
228. Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok ASF. Long-term efficacy of nucleoside
monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-
positive donor livers. Hepatol Int; 4: 707-715, 2010. PMC2994614.
Anna Suk-Fong Lok 12/5/2016 46
229. Volk ML, Piette JD, Singal AS, Lok ASF. Chronic disease management for patients with
cirrhosis. Gastroenterol 139: 14-6, 2010. PMID: 20553725.
230. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of
hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a
systematic review. J Hepatol 53: 348-56, 2010. PMID: 20483498.
231. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, de Santo JL, Lee WM,
DiBisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok ASF, and
the HALT-C Trial Group. Outcome of sustained virological responders in the Hepatitis C
Antiviral Long-term Treatment against Cirrhosis Trial. Hepatology; 52: 833-44, 2010.
PMC2932862
232. Fontana RJ, Dienstag JL, Bonkovsky H, Sterling R, Naishadham D, Goodman Z, Lok A,
Wright E, Su G, and the HALT-C Trial Group. Serum fibrosis markers are associated
with liver disease progression in non-responder patients with chronic hepatitis C. Gut
59:1401-9, 2010. PMC3740000
233. Pockros PJ, Fayez M. Hamzeh FM,
Paul Martin P,
Lentz E, Zhou X, Govindarajan S,
and
Lok AS. Histologic outcomes in hepatitis C-infected patients with varying degrees of
virologic response to interferon-based treatments. Hepatology; 52: 1193-1200, 2010.
PMID: 20658462.
234. Chotiyaputta W, Degertekin B, McKenna BJ, Samala N, Fontana RJ, Lok ASF.
Characteristics of chronic hepatitis B patients who underwent liver biopsies. J Viral
Hepat; 18: 792-803, 2011. PMC3003777
235. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok ASF. Persistence and adherence
to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol; 54: 12-8, 2011.
PMID: 20888661.
236. Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana
RJ, and the HALT-C Trial Group. No increase in depression with low-dose maintenance
peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord; 129: 205-
12, 2011. PMC3025085
237. Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekein B,
Lok A and the NIH HBV OLT Study Group. Clinical outcomes of liver transplantation
for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin
Transplant; 25: E152-62, 2011. PMC3771871
238. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT,
Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan
TR, and the HALT-C Trial Group. Maintenance peginterferon therapy and other factors
associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Gastroenterol; 140: 840-9, 2011. PMC3057272
Anna Suk-Fong Lok 12/5/2016 47
239. Volk ML, Reichert HA, Lok ASF, Hayward RA. Variation in organ quality between liver
transplant centers. Am J Transpl; 11: 958-64, 2011. PMC3175797
240. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, and the
HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated
with hepatocellular carcinoma in patients with chronic hepatitis C. Hepatology; 54: 434-
42, 2011. PMC3134544
241. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff
LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS,
Morishima C, Stoddard AM, Everhart JE, for the HALT-C Trial Group. A prospective
study of the rate of progression in compensated, histologically advanced chronic hepatitis
C. Hepatology; 54: 396-405, 2011. PMC3144992
242. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T,
and Lok ASF. Virological breakthrough and resistance in patients with chronic hepatitis
B receiving nucelos(t)ide analogs in clinical practice. Hepatology; 53: 1854-63, 2011.
PMID: 21618260.
243. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, and Lok ASF.
Adherence to nucleos(t)ide analaogues for chronic hepatitis B in clinical practice and
correlation with virological breakthroughs. J Viral Hepat; 19: 205-12, 2012.
244. Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter
mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21.
Gastroenterol 141: 1412-21, 2011. PMC3186859
245. O’Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML,
Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM, and the HALT-C Trial Group. An
IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
PLos One 2011; 6:e20904. PMC3132753
246. Qin Y, Tang X, Garcia T, Hussain M, Zhang J, Lok A, Wands J, Li J, Tong S. Hepatitis B
virus genotype C isolates with wild-type core promoter sequences replicate less
efficiently than genotype B isolates but possess higher virion secretion capacity. J Virol;
85: 10167-77, 2011. PMC3766736
247. Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok
AS, Omary MB, and the HALT-C Trial Group. Mallory-Denk bodies are associated with
outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol
Hepatol; 9: 902-9, 2011. PMC3400531
248. Ghany MG, Kim H, Stoddard A, Wright EC, Seeff LB, Lok ASF, and the HALT-C Trial
Group. Predicting Clinical Outcomes in Chronic Hepatitis C Using Baseline and Follow-
up Laboratory Data from the Hepatitis C Long-term Treatment Against Cirrhosis Trial.
Hepatology; 54: 1527-37, 2011. PMC3718548
Anna Suk-Fong Lok 12/5/2016 48
249. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL,
Lok AS, and the HALT-C Trial Group. Frequency of Elevated Hepatocellular Carcinoma
(HCC) Biomarkers in Patients with Advanced Hepatitis C. Am J Gastroenterol; 107: 64-
74, 2012. PMC3903319
250. Rakoski M, McCammon R, Piette J, Iwashyna T, Marrero J, Lok ASF, Volk M. Burden
of cirrhosis on older Americans and their families: analysis of the Health and Retirement
Study. Hepatology; 55: 184-191, 2012. PMC3462487
251. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital Re-Admissions among
Patients with Decompensated Cirrhosis. Am J Gastroenterol; 107: 247-52, 2012.
PMC3470789
252. Snider NT, Weerasinghe SVW, Singla A, Leonard JM, Hanada S, Andrews PC, Lok AS,
Omary MB. Energy determinants GAPDH and NDPK act as genetic modifiers for
hepatocyte inclusion formation. J Cell Biol 195: 217-29, 2011. PMC3198167
253. Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ and the HALT-C
Trial Group. Predicting cirrhosis and clinical outcomes in patients with advanced chronic
hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics 21: 851-
60, 2011. PMC3215092
254. Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, Lok ASF, Word A, Lee WM
and the Acute Liver Failure Study Group. Two Distinct Subtypes of Hepatitis B Virus-
Related Acute Liver Failure Are Separable By Quantitative Serum IgM anti-HBc and
HBV DNA Levels. Hepatology; 55: 676-84, 2012. PMC3272543
255. Volk ML, Tocco RS, Pelletier SJ, Zikmund-Fisher BJ, Lok AS. Patient decision making
about organ quality in liver transplantation. Liver Transpl; 13: 1387-93, 2011.
PMC3227783
256. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS, for the
HALT-C Trial Group. YKL-40 genetic polymorphisms and the risk of liver disease
progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int; 32:
665-74, 2011. PMC3299849
257. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single topic
conference on “chronic viral hepatitis – strategies to improve effectiveness of screening
and treatment”. Hepatology; 55: 307-315, 2012. PMID: 22105599.
258. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R,
Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, eley T, Guo T,
Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C
genotype 1. N Engl J Med; 366: 216-24, 2012. PMID: 22256805.
259. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, Liu F, Zhang HY, Zhang HH, Du
SC, Jin Q, Qin H, Lok AS, Wei L. IL28B genetic variants and gender are associated with
Anna Suk-Fong Lok 12/5/2016 49
spontaneous clearance of hepatitis C virus infection. J Viral Hepat; 19: 173-81, 2012.
PMID: 22329371.
260. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS,
Marrero JA. Effectiveness of hepatocellular carcinoma surveillance in patients with
cirrhosis. Cancer Epidemiol Biomarkers Prev 21: 793-9, 2012. PMID 22374994.
261. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for
liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently
normal ALT: a systematic review. J Hepatol; 57: 196-201, 2012. PMID 22450396.
262. Thai H, Campo DS, Lara J, Dimitrova Z, Ramachandran S, Xia G, Ganova-Raeva L, Teo
CG, Lok A, Khudyakov Y. Convergence and coevolution of hepatitis B virus drug
resistance. Nature Commun doi: 10.1038/ncomms1794 (2012). PMC3337990
263. Qin S, Zhou Y, Lok AS, Tsodikov A, Yan X, Gray L, Yuan M, Moritz RL, Galas D,
Omenn GS, Hood L. SRM targeted proteomics in search for biomarkers of HCV-induced
progression of fibrosis to cirrhosis in HALT-C patients. Proteomics; 8: 1244-52, 2012.
PMID: 22577025.
264. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS,
Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in
Hepatic Inflammation Is Associated with Less Fibrosis Progression and Fewer Clinical
Outcomes in Advanced Hepatitis C. Am J Gastroenterol; 107: 1388-98, 2012.
PMC3865099
265. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D,
Lovegren M, Cohen D, Llamoso C. Efficacy of Entecavir with or without Tenofovir
Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients with Chronic Hepatitis B.
Gastroenterology 143: 619-628, 2012. PMID: 22643350.
266. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS, Saab S, Shiffman ML, Al-
Osaimi AMS, Kulik L, Gillespie BW, Everhart JE and the A2ALL Study. A Randomized
Controlled Trial of Pretransplant Antiviral Therapy to Prevent Recurrence of Hepatitis C
after Liver Transplantation. Hepatology; 57: 1752-62, 2013. PMC3510348
267. Kulik LM, Fisher RA, Rodrigo DR, Brown RS, Friese CE, Shaked A, Everhart JE,
Everson GT, Hong JC, Hayashi PH, Berg CL, Lok ASF and the A2ALL Study Group.
Outcomes of Living and Deceased Donor Liver Transplant Recipients with
Hepatocellular Carcinoma: Results of the A2ALL Cohort. Am J Transpl 12:2997-3007,
2012. PMC3523685
268. Kwei K, Tang X, Lok AS, Sureau C, Garcia T, Li J, Wands J, and Tong S. Impaired
Virion Secretion by Hepatitis B Virus Immune Escape Mutants and its Rescue by Wild-
Type Envelope Proteins or a Second-Site Mutation. J Virol; 87: 2352-7, 2013.
PMC3571463
Anna Suk-Fong Lok 12/5/2016 50
269. Singal AG, NehraM, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM.
Detection of Hepatocellular Carcinoma at Advanced Stages among Patients in the HALT-
C Trial: Where Did Surveillance Fail? Am J Gastroenterol; 108: 425-432, 2013. PMID:
23337478.
270. Huang Y, Tai AW, Tong S, Lok AS. HBV core promoter mutations promote cellular
proliferation through E2F1-mediated upregulation of S-phase kinase associated protein 2
transcription. J Hepatol 58: 168-73, 2013. PMC3898818
271. Snider NT, Griggs NW, Singla A, Moons DS, Weerasinghe SV, Lok AS, Ruan C, Burant
CF, Conjeevaram HS, Omary MB. CD73 (ecto-5’-nucleotidas) hepatocyte levels differ
across mouse strains and contribute to Mallory-Denk body formation. Hepatology; 58:
1790-1800, 2013. PMC3796030
272. Chu D, Yang JD, Lok AS, Tran T, Martins EB, Fagan E, Rousseau F, Kim WR. Hepatitis
B screening and vaccination practices in Asian American primary care. Gut Liver 2013;
7: 450-7. PMC3724034
273. Singal AG, Mukherjee A, Elmunzer BJ, Higgins PDR, Lok AS, Zhu J, Marrero JA,
Waljee AK. Machine learning algorithms outperform conventional regression models in
predicting development of hepatocellular carcinoma. Am J Gastroenterol 108:1723-30,
2013. PMID: 24169273.
274. Sharma P, Hosmer A, Appelman H, McKenna B, Jafri M, Sullivan P, Fontana RJ, Lok
AS. Immunologica, dysfunction during or after antiviral therapy for recurrent hepatitis C
reduces graft survival. Hepaol Int 7:990-9, 2013. PMC4371864
275. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KT, Hassanein T, Jacobson I,
Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR. Everson GT,
Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D,
Hindes R, Symonds W, Pasquinelli C, Grasela DM, for the AI44040 Study Group.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV. N Engl J
Med 370: 211-21, 2014. PMID: 24428467.
276. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, Marcellin P,
Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-Rotolo M, Yu F,
McPhee F, Grasela DM, Pasquinelli C. Randomized trial of daclatasvir and asunaprevir
with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol;
60: 490-9, 2014. PMID: 24444658.
277. Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in
hepatitis B screening at the onset of chemotherapy in a large US cancer center. BMC
Cancer 13:534.doi:10.1186/11471-2407-13-54, 2013. PMC3827843
278. Terrault NA, Stravitz RT, Lok ASF, Everson GT, Brown RS, Kulik LM, Olthoff KM,
Saab S, Adeyi O, Argo CK, Everhart JE, Rodrigo DR, and the A2ALL Study Group.
Anna Suk-Fong Lok 12/5/2016 51
Hepatitis C disease severity in living versus deceased donor liver transplant recipients –
an extended observation study. Hepatology 59: 1311-9, 2014. PMC4118586
279. Hwang JP, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok ASF.
Hepatitis C screening in cancer patients receiving chemotherapy. J Oncol Pract 10: e167-
74, 2014. PMC4018458
280. Ghany M, Perrillo R, Li R, Belle SH, Janssen HLA, Terrault NA, Shuhart MC, Lau DTY,
Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SHB, Ganova-Raeva LM,
Chang KM, Lok ASF for the Hepatitis B Research Network (HBRN). The Hepatitis B
Research Network (HBRN): Characteristics of the Adult Cohort in North America
Reflect the Diversity in Country of Origin and Genotype. Clin Gastroenterol Hepatol; 13:
183-92, 2015. PMID 25010003.
281. Wu E, Chen X, Guan Z, Cao C, Rao H Feng B, Chan M, Fu S, Lin A, Wei L, Lok AS. A
comparative study of patients’ knowledge about hepatitis C in the United States and in
urban and rural China. Hepatol Int 8:58-66, 2014. PMID: 25788380.
282. Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcome of chronic hepatitis B
patients who do not meet criteria for antiviral treatment at presentation. Clin
Gastroenterol and Hepatol; 13: 193-201 2015. PMID: 25041863.
283. Konerman MA, Yapali S, Lok AS. Systematic review: Identifying patients with chronic
hepatitis C in need of early treatment and intensive monitoring - predictors and predictive
models of disease progression. Aliment Pharmacol & Ther; 40: 863-79, 2014. PMID:
25164152.
284. Talaat N, Yapali S, Fontana RJ, Conjeevaram HS, Lok AS. Changes in characteristics of
hepatitis C patients seen in a liver center in the United States during the last decade. J
Viral Hepat 22:481-8, 2015. PMID: 25311830.
285. Wu E, Wang T, Lin T, Chen X, Guan Z, cao C, Rao H, Yang M, Feng B, Pui S, Chan M,
Fu S, Lin A, Wei L, Lok AS. A Comparative Study of Patients’ Attitudes toward Clinical
Research in the United States and Urban and Rural China. Clin Transl Sci; 8: 123-31,
2015. PMID: 25588611.
286. Dan YY, Wong JB, Hamid SS, Han KH, Jia JD, Liu CJ, Piratvisuth T, Lok ASF, Lim
SG. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia
Pacific countries. Hepatol Int 2014; 8: 382-394.
287. Konerman MA, Zhang Y, Zhu J, Higgins PDR, Lok ASF, Waljee AK. Improvement of
predictive models of risk of disease progression in chronic hepatitis C by incorporating
longitudinal data. Hepatology 61: 1832-41, 2015. PMID: 25684666.
288. Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, Lau D,
Lisker-Melman M, Sanyal A, Lok AS for the HBRN. Diabetes and Prediabetes in Patients
Anna Suk-Fong Lok 12/5/2016 52
with Hepatitis B Residing in North America. Hepatology 62: 1364-74, 2015. PMID:
26390278.
289. Tayob N, Lok ASF, Do KA, Feng Z. Improved detection of hepatocellular carcinoma
using a longitudinal α–fetoprotein screening algorithm. Clin Gastroenterol Hepatol 14:
469-475, 2016. PMID: 26260109.
290. Patel A, Yapali S, Lok AS. Admissions for hepatitis B reactivation in patients receiving
immunosuppressive therapy remain unchanged from 1999 to 2014. Hepatol Int 10: 139-
146, 2016. PMID: 26272106.
291. Lok AS, McMahon BJ, Brown RS, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab
F, Benhhadra K, Mouchli MA, Singh S, Mohamed EA. Abu Dabrh AM, Larry PJ, Wang
Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B virus infection in
adults: a systematic review and meta-analysis. Hepatology; 63: 284-306, 2016. PMID:
26566246.
300. Jonas MM, Lok ASF, McMahon BJ, Brown RS, Wong JB, Ahmed A, Farah W, Mouchli
M, Singh S, Larry PJ, Murad MH, Mohammed K. Antiviral therapy in management of
chronic hepatitis B virus infection in children: a systematic review and meta-analysis.
Hepatology; 63: 307-318, 2016. PMID: 26566163.
301. Ahn J, Lee H, Lim J, Pan C, Nguyen M, Kim WR, Trinh H, Chu D, Tran T, Min A, Do S,
Te H, Reddy R, and Lok A. Entecavir safety and effectiveness in a national cohort of
treatment-naïve chronic hepatitis B patients in the US – the ENUMERATE study.
Aliment Pharmacol Ther; 43: 134-144, 2016. PMID: 26510638.
302. Brown RS, McMahon BJ, Lok ASF, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Larry
PJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B virus infection
during pregnancy: a systematic review and meta-analysis. Hepatology; 63: 319-333, 2016.
PMID: 26565396.
303. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK,
Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith
JW, Levine DL, Traum D, Ho S, Valiga M, Johnson GS, Doo E, Lok ASF, Chang KM
for the HBRN. HBV-specific and global T-cell dysfunction in chronic hepatitis B.
Gastroenterol; 150: 684-695, 2016. PMID: 26684441.
304. Konerman MA, Brown M, Zheng Y, Lok ASF. Dynamic prediction of risk of liver-
related outcomes in chronic hepatitis C using routinely collected data. J Viral Hepat 23:
455-463, 2016. PMID: 26893198.
305. Lerrigo R, Beste LA, Leipertz SL, Green PK, Lok ASF, Kogut MJ, Ioannou GN.
Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients
in the VA Healthcare system. Eur J Gastroenterol Hepatol 28: 667-675, 2016. PMID:
26886386.
Anna Suk-Fong Lok 12/5/2016 53
306. Thomson M, Konerman MA, Choxi H, Lok AS. Primary care physician perspectives on
hepatitis C management in the era of direct-acting antiviral therapy. Dig Dis Sci (in press)
2016. PMID: 26957497.
307. Huang J, Guan ML, Balch J, Wu E, Rao H, Lin A, Wei L, Lok AS. Survey of hepatitis B
knowledge and stigma among chronically infected patients and uninfected persons in
Beijing, China. Liver Int; 36:1595-1603, 2016. PMID: 27206379.
308. Lok AS, Pan CQ, Han SB, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A,
Subramanian GM, McHutchison JG, Ferrari C, Lee H, Gordon SC, Gane EJ. Randomized
phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with
chronic hepatitis B. J Hepatol; 65: 509-516, 2016. PMID: 27210427.
309. Yang M, Wu E, Rao H, Du FH, Xie A, Cheng S, Rodd C, Wei L, Lok A. A comparative
study of liver disease care in the United States and Urban and Rural China. Dig Dis Sci;
61: 2847-2856, 2016. PMID: 27256156.
310. Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, Mannalithara A, Te H, Reddy
KR, Trinh H, Chu D, Tram T, Lau D, Leduc TS, Min A, Le LT, Bae H, Tran SV, Do S,
Hann HW, Wong C, Han S, Pillai A, Park JS, Tong M, Scaglione S, Woog J, Kim WR.
Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated
with entecavir: results of the ENUMERATE Study. Am J Gastroenterol; 111: 1297-1304,
2016. PMID: 27325221.
311. Gordon FD, Goldberg DS, Goodrich NP, Lok AS, Verna EC, Selzner N, Stravitz RT,
Merion RM. Recurrent PSC in the A2ALL Study: comparison of risk factors between
living and deceased donor recipients. Liver Transpl; 22: 1214-1222, 2016. PMID:
27339253.
312. Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, Lok ASF,
Levy G, Kulik L, Abecassis M, Shaked A. Acute rejection and survival after living or
deceased donor liver transplantation. Clin Gastroenterol Hepatol (in press), 2016. PMID:
27567694.
313. Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V.
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular
carcinoma: an analysis of the SEER-Medicare Database. Hepatology; 65: 122-133, 2017.
PMID: 27770556.
314. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Vargas HE, Galati JS, Morelli G, Everson
GT, Kwo PY, Brown RS, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Terrault
NA, Fried MW, Manns MP for the HCV-TARGET Study Group. All-oral, direct-acting
antiviral therapy in HCV-advanced liver disease is effective in real-world practice:
observations through HCV-TARGET database. Aliment Pharm Ther; 45: 115-126, 2017.
PMID. 27790729.
Anna Suk-Fong Lok 12/5/2016 54
315. Hassan MA, Kim WR, Li R, Smith CI, Fried MW, Sterling RK, Ghany MG, Wahed AS,
Ganova-Raeva LM, Roberts LR, Lok ASF for the Hepatitis B Research Network.
Characteristics of US-born versus foreign-born Americans of African descent with
chronic hepatitis B. Am J Epidemiol (in press) 2017.
316. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok
AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fired MW,
Nelson DR; HCV-TARGET Study Group. Effectiveness of ledipasvir-sofosbuvir
combination in patients with hepatitis C virus infection and factors associated with
sustained virologic response. Gastroenterol; 151: 1131-1140, 2016. PMID: 27565882.
317. Cheng S, Li E, Lok AS. Predictors and barriers to hepatitis B screening in a Midwest
Suburban Asian population. J Community Health (in press), 2016. PMID: 27770375.
Article I. Invited Editorials/Reviews (peer-reviewed and non peer-reviewed)
1. Thomas HC and Lok ASF. The use of antiviral drugs in chronic hepatitis B virus
infection. Hospital Update Jan. 49-60, 1984.
2. Thomas HC and Lok ASF. The immunopathology of autoimmune and hepatitis B virus
induced chronic hepatitis. Seminars in Liver Disease 4:36-46, 1984.
3. Lok ASF, Lai CL and Lam SK. HBsAg positive patients: What to do? Medical progress
ADIS Press (Guest editorial). 12:7-10, 1985.
4. Lok ASF. Antiviral therapy of chronic hepatitis B virus infection. Journal of
Gastroenterology and Hepatology. 1:169-79, 1986.
5. Lok ASF. Adenine arabinoside and its 5'-monophosphate ester in the treatment of
chronic hepatitis B virus infection. Proceedings of the IXth
International Congress of
Infectious and Parasitic Diseases. Munich July 20-26, 1986. Ed W Margel, W Lang and
E Gabler - Sandberger MMV Medizin Verlag Munchen pp 87-9, 1986.
6. Lok ASF. Update on Management of Chronic Hepatitis B Infection. Philippine J
Microbiology & Infectious Diseases 15:12-5, 1986.
7. Lok ASF. Acute viral hepatitis in chronic carriers of hepatitis B virus: different patterns
in different places. Hepatology 10:252-3, 1989.
8. Lok ASF, Lai CL, W PC, Lau JYN, Leung EKY, Wong LSK. Treatment of chronic type
B hepatitis with interferon: Experience in Asian patients. Sem Liver Dis. 9:249-53,
1989.
Anna Suk-Fong Lok 12/5/2016 55
9. Lok ASF, Lai CL, Wu PC, Lau JYN, Leung EKY, Wong LSK, Fung YL. Alpha
interferon treatment in Chinese patients with chronic hepatitis B. J Hepatol 11
(Suppl 1):S121-5, 1990.
10. Lok ASF. Hepatitis vaccines. In Current Perspectives in Clinical Hepatology, ed. Jones
DB. Excerpta Medica, Sydney 32-6, 1990.
11. Lok ASF. How should asymptomatic hepatitis B virus carriers be treated? CME Review,
Singapore 1:24-5, 1991.
12. Lok ASF, Lai CL. Treatment of chronic hepatitis B virus infection in children. In
“Therapy in Liver Diseases”, ed. Rodés J and Arroyo V. Doyme SA, Spain pp. 259-66,
1991.
13. Lok ASF. Natural history and control of perinatally acquired hepatitis B virus infection.
Dig Dis 10:46-52, 1992.
14. Lok ASF. Alpha interferon therapy for chronic hepatitis B virus infection in children and
oriental patients. J Gastroenterol & Hepatol 6 (Suppl 1):15-7, 1991.
15. Lok ASF. Hepatitis C: Commentary from Southeast Asia. Medical Progress
19:25,1992.
16. Lok ASF. Antiviral therapy of chronic hepatitis B virus infection. In advances in
hepatology 1990, ed. Wang BE, Yao GB, Yan WY. Shanghai Science and Technology
Press, Shanghai pp: 141-58, 1991.
17. Lok ASF. Hepatitis B vaccination in Hong Kong. J Gastro and Hepatol 8 (Suppl 1):27-
9, 1993.
18. Lok ASF. Chronic hepatitis B virus infection in children. Gastroenterolgia y
Hepatologia 16:391-6, 1993.
19. Lok ASF. Antiviral therapy for the Asian patient with chronic hepatitis B. Sem Liver
Dis 13:360-6, 1993.
20. Lok ASF, Gerber MA. Clinicopathology Conference: A young woman with chronic
hepatitis. Hepatology 17:739-45, 1993.
Anna Suk-Fong Lok 12/5/2016 56
21. Lok ASF, Soldevila-Pico C. Epidemiology and serologic diagnosis of hepatitis E. J
Hepatol 20:567-9, 1994.
22. Lok ASF, Ghany MG, Gerber MA. Clinicopathology Conference: A young woman with
cirrhosis: Autoimmune hepatitis vs alpha-1-antitrypsin deficiency. Hepatology 19:1302-
6, 1994.
23. Lok ASF. Treatment of chronic hepatitis B. J Viral Hep 1:105-24, 1994.
24. Geders JM, Haque S, Tesi RJ, Gerber MA, Lok ASF. Clinico-pathology conference: A
young man with a solitary hepatic mass. Hepatology 22:655-9, 1995.
25. Lok ASF. Does interferon therapy for chronic hepatitis B reduce the risks of developing
cirrhosis and hepatocellular carcinoma? Hepatology 22:1336-8,1995.
26. McDonnell WM and Lok ASF. Testing for Hepatitis C Virus RNA in Serum: When and
How? Viral Hepatitis Reviews 2:81-3, 1996.
27. McDonnell WM, Lok ASF, Fendrick AM. Diagnostic and treatment strategies in
hepatitis C virus infection. J Clin Outcomes Management 3:15-24, 1996.
28. McDonnell WM, Lok ASF. Viral hepatitis. Current Opinion in Gastroenterology
13:228-234, 1997.
29. Fontana RJ, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology 26:234-
7, 1997.
30. Lok ASF, Gunaratnam NT. Diagnosis of Hepatitis C. Hepatology 26:485-565, 1997.
31. Lok ASF. Prospective study of hepatocellular carcinoma and liver cirrhosis in
asymptomatic chronic hepatitis B virus carriers. Adv Gastroenterology, Hepatology and
Clin Nutr 2:173-175, 1997.
32. Lok ASF. Combination Therapy for chronic hepatitis B. Hepatologia Clinica 6:Suppl 1, 5
51-58, 1998.
33. Chan HLY and Lok ASF. Hepatitis B-clinical perspective: Adults. In Clinics in Liver
Diseases, ed. WM Lee, WB Saunders 3:291-308,1999.
34. Hussain M, Lok ASF. Mutations in Hepatitis B virus polymerase gene associated with
Anna Suk-Fong Lok 12/5/2016 57
antiviral treatment for hepatitis B. J Viral Hep 6:183-194,1999.
35. Lok ASF. Hepatitis B infection: pathogenesis and management. J. Hepatol 32 (Suppl 1):
78-97,2000.
36. Peters MG, Shouval D, Bonham A, Vierling JM, Lok ASF. Post-transplantation: future
Therapies. Sem Liver Disease 20 (Suppl 1): 19-24, 2000.
37. Lok ASF. Lamivudine Therapy for chronic hepatitis B – is longer duration of treatment
better? Gastroenterology 119: 263-6, 2000. (Editorial)
38. Fontana, RJ, Lok ASF. Lamivudine treatment in patients with decompensated hepatitis B
cirrhosis for whom and when? J. Hepatol 33: 329-332, 2000. (Editorial)
39. Chu CJ, Lok ASF. Does OKT3 increase the risk of recurrent hepatitis B in patients
transplanted for hepatitis B? Liver Transpl. 6:810-812, 2000.
40. Conjeevaram H, Lok ASF. Occult hepatitis B virus infection: A hidden menace.
Hepatology (editorial) 34:204-206, 2001.
41. Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B 2000: Report of a
workshop. Gastroenterology 120:1828-1853, 2001.
42. Lok AS, McMahon BJ. AASLD Practice Guideline – Chronic Hepatitis B. Hepatology
34:1225-1241, 2001.
43. Chu CJ, Lok ASF. Clinical utility in quantifying serum DNA levels using PCR assays. J
Hepatol (editorial), 36:549-551, 2002.
44. Chu CJ, Lok ASF. Clinical significance of hepatitis B virus genotypes. Hepatology
(editorial), 35(5):1274-6, 2002.
45. Lok ASF. Perspective on Chronic Hepatitis B. N Engl J Med, 346:1682-3, 2002.
46. Fontana RJ, Lok ASF. Combination of HBIG and Lamivudine resistant mutations: a
formula for trouble? Liver Transplantation 8:1082-4, 2002
47. Fontana RJ, Lok ASF. Non-invasive monitoring of patients with chronic Hepatitis C.
Hepatology 36:S57-64, 2002
Anna Suk-Fong Lok 12/5/2016 58
48. Lok ASF. Prevention of recurrent Hepatitis B post-liver transplantation. Liver
Transplantation 8:S67-73, 2002
49. Huang MA, Lok AS. Natural history of Hepatitis B and outcome for liver transplantation.
Clin Liver Dis 7:521-536, 2003.
50. Conjeevaram H, Lok AS. Management of Hepatitis B. J Hepatol 38:S90-103, 2003.
51. Wai CT, Lok AS. Treatment of Hepatitis B. J Gastroenterol 37:771-8, 2002.
52. Lok ASF. Hepatitis B: Progress in the last decade. Sem Liver Dis 23:1-4, 2003.
53. Lok ASF. New treatment of chronic hepatitis B. Sem Liver Dis 24 (suppl 1):77-82, 2004.
54. Lok ASF, McMahon BJ. AASLD Practice Guidelines: Hepatitis B, Update of
recommendations. Hepatology. 39:857-861, 2004.
55. Marrero JA, Lok ASF. Occult hepatitis B virus infection in patients with hepatocellular
carcinoma: innocent bystander, cofactor or culprit? Gastroenterology (editorial) 126:347-
350, 2004.
56. Fung SK, Lok ASF. Treatment of Chronic Hepatitis B. Clin Gastro and Hepatol 2:839-
848, 2004.
57. deFranchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A,
Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D – EASL Jury. EASL
International Consensus Conference on Hepatitis B, 13-14 September 2002, Geneva,
Switzerland. J Hepatol 39 (suppl 1): S3-S25, 2003.
58. Fung SK, Lok ASF. Viral Hepatitis 2003. Curr Opin Gastroenterol 20:241-7, 2004.
59. Lok ASF. Prevention of hepatitis B virus-related hepatocellular carcinoma.
Gastroenterology 127 (suppl 1): S303-9, 2004.
60. Marrero JA, Lok ASF. Newer markers of hepatocellular carcinoma. Gastroenterology 127
(suppl 1): S113-9, 2004.
61. Fung SK, Lok ASF. Hepatitis B Virus Genotypes: Do they play a role in outcome of HBV
infection? Hepatology 40:790-2, 2004.
Anna Suk-Fong Lok 12/5/2016 59
62. Fung SK, Lok ASF. Management of hepatitis B patients with antiviral resistance.
Antiviral therapy 9:1013-26, 2004.
63. Fung SK, Lok ASF. Management of patients with hepatitis B virus-induced cirrhosis. J
Hepatol 42 (suppl 1):S54-64, 2005.
64. Fung SK, Lok ASF. Drug insight: Nucleoside and nucleotide analogue inhibitors for
hepatitis B. Nature Clinical Practice in Gastroenterology and Hepatology 1:90-97, 2004.
65. Lok ASF. Liver Transplantation for Patients with Lamivudine-resistant HBV: What is the
Optimal Prophylactic Strategy? Liver Transpl 11:490-493, 2005.
65. Fung SK, Lok ASF. Update on viral Hepatitis 2004. Curr Opin Gastroenterol 21:300-307,
2005.
66. Lok AS. The maze of hepatitis B treatments. (editorial) N Engl J Med 352:2743-6, 2005.
67. Yim HJ and Lok AS. Natural history of chronic hepatitis B virus infection: what we knew
in 1981 and what we know in 2005. Hepatology 43:S173-S181, 2006.
68. Wong SN and Lok AS. Treatment of hepatitis B: Who, when and how? (editorial) Arch
Intern Med (editorial) 166:9-12, 2006.
69. Wong SN and Lok AS. Update on Viral Hepatitis: 2005. Curr Opin Gastroenterol
22:241-7, 2006.
70. Osborn MK and Lok AS. Antiviral options for the treatment of chronic hepatitis B. J
Antimicrob Chemother 57:1030-4, 2006.
71. Sharma P and Lok A. Viral Hepatitis and Liver Transplantation. Semin Liver Dis 26:285-
297, 2006.
72. Wong SN and Lok AS. Tenofovir disoproxil fumarate: role in hepatitis B treatment.
Hepatology (editorial) 44:309-313, 2006.
73. Kang H and Lok AS. Endpoints for clinical trials on treatment of hepatitis C. J Hepatol
(editorial) 45:473-5, 2006.
74. Tan J and Lok AS. Antiviral Therapy for Pre- and Post- Liver Transplantation Patients
Anna Suk-Fong Lok 12/5/2016 60
with Hepatitis B. Liver Transpl (editorial) 13:323-6, 2007.
75. Lok ASF, McMahon BJ. AASLD Practice Guidelines: Hepatitis B. Hepatology 45:507-
539, 2007. Corrections Hepatology 45:1347, 2007.
76. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of Hepatitis B:
Summary of a Clinical Research Workshop. Hepatology 45:1056-67, 2007.
77. Tan J and Lok AS. Update on Viral Hepatitis 2006. Curr Opin Gastro 23: 263-7, 2007.
78. Lok AS. Navigating the Maze of Hepatitis B Treatments. Gastroenterology 132:1586-94,
2007.
79. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M, Pawlotsky JM, Liaw YF,
Mizokami M, Kuiken C. Antiviral drug-resistant HBV: Standardization of nomenclature
and assays and recommendations for management. Hepatology 46:254-265, 2007.
80. Degertekin B and Lok AS. When to start and stop hepatitis B treatment: can one set of
criteria apply to all patients regardless of age at infection? Annals Intern Med 147:62-64,
2007.
81. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this
monster from growing? J Viral Hepat 14: (suppl 1): S29-36, 2007.
82. Degertekin B and Lok AS. Monitoring antiviral resistance in patients receiving
nucleos/tide analogue therapies for hepatitis B: which method should be used? J Hepatol
48: 892-4, 2008. PMID: 18433924
83. Degertekin B and Lok AS. Update on Viral Hepatitis 2007. Curr Opin Gastroenterol 24:
306-311, 2008. PMID: 18408458
84. Llovet JM and Lok A. Hepatitis B virus genotype and mutants: risk factors for
hepatocellular carcinoma. JNCI (editorial) 100:1121-3, 2008. PMC2720710
85. Lok ASF. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver
transplant setting? Liver Transpl; 14 (suppl 2): S8-S14, 2008. PMID: 18825720
86. Chotiyaputta W and Lok AS. Role of antiviral therapy in the prevention of perinatal
transmission of HBV infection. J Viral Hepat 16: 91-3, 2009. PMID: 18165766
Anna Suk-Fong Lok 12/5/2016 61
87. Volk ML and Lok AS. Is family history of liver cancer a risk factor for hepatocellular
carcinoma? J Hepatol 50:247-8, 2009. PMID: 19070916
88. Degertekin B and Lok AS. What is the optimal regimen for preventing hepatitis B
recurrence after liver transplantation? Nature Clin Pract Gastroenterol Hepatol 6:68-9,
2009. PMID: 19092788
89. Degertekin B and Lok AS. Update on Viral Hepatitis 2008. Curr Opin Gastroenterol 25:
180-5, 2009. PMID: 19387254
90. Lok ASF. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here
yet? J Hepatol 51: 416-8, 2009. PMID: 19410323
91. Degertekin B and Lok ASF. Indications for therapy in hepatitis B. Hepatology 49: S129-
137, 2009. PID: 19399799
92. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental
hepatitis C virus infection. N Engl J Med 360: 1902-6, 2009. PMID: 19403909
93. Chotiyaputta W and Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol
6: 453-462, 2009. PMID: 19581904
94. Fleischer RD and Lok ASF. Myopathy and Neuropathy associated with Nucleos(t)ide
Analog Therapy for Hepatitis B. J Hepatol 51:787-91, 2009. PMID: 19665816
95. Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol
33: 911-5, 2009. PMID: 19577871
96. Lok AS and McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50: 661-2,
2009. PMID: 19714720
97. Lok AS. EASL International Awardee 2009: Professor Ding-Shinn Chen. J Hepatol 51:
615-6, 2009. PMID: 19760808
98. Lok AS. Should antiviral treatment be extended to patients with chronic hepatitis B and
mildly elevated alanine aminotransferase? Hepatology (editorial) 51: 1107-9, 2010.
PMID: 20162620.
99. Jafri SMR and Lok AS. Antiviral therapy for chronic hepatitis B. Clinics in Liver Dis 14:
425-38, 2010. PMID: 20638023.
Anna Suk-Fong Lok 12/5/2016 62
100. El-Serag H, Lok AS, Thomas DL. The dawn of a new era: transforming our domestic
response to hepatitis B and C. Gastroenterol 138:1225-30, 2010. PMID: 20176024.
101. Lok ASF, Kim WR, El-Serag H, Maddrey WC. The dawn of a new era: transforming our
domestic response to hepatitis B & C – activity 1: Overview of the viral hepatitis
problem. J Family Practice 59 (supplement): S11-6, 2010. PMID: 20398585.
102. Chotiyaputta W and Lok ASF. Endpoints of hepatitis B treatment. J Viral Hepat 17: 675-
84, 2010. PMID20840331.
103. Lok AS. Diagnostic and Therapeutic Advances in Hepatology – Drug therapy: Tenofovir.
Hepatology; 52: 743-7, 2010. PMID: 20597070.
104. Hongthanakorn C and Lok ASF. New Pharmacological Therapies in Chronic Hepatitis B.
Gastroenterol Clinics of N America; 39: 659-680, 2010. PMID:20951923.
105. Brunetto MR, Lok AS. New approaches to optimize treatment response in chronic
hepatitis B. Antivir Ther; 15 (suppl 3): 61-8, 2010. PMID: 21041905.
106. Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J
Gastroenterol Hepatol 26: 221-7, 2011. PMID: 21070361.
107. Huang Y and Lok AS. Viral factors and outcomes of chronic HBV infection. Am J
Gastroenterol (editorial) 106: 93-5, 2011. PMID: 21212756.
108. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol; 8: 275-84, 2011.
PMID 21423260.
109. Lok AS. Authorship: Who should be included and how should it be determined?
Gastroenterol; 141: 786-8, 2011. PMID: 21782816.
110. Hatzakis A, Wait S, Bruix J, Buti M, Caballo M, Cavaleri M, Colombo M, Delarocque-
Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, gore C, Lok ASF, Manns
M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M,
Rodot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P,
Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, and Janssen HLA. The state of
hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral
Hepat 18 (Suppl 1): 1-16, 2011. PMID: 21824223.
111. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther;
16: 787-95, 2011. PMID: 21900710.
Anna Suk-Fong Lok 12/5/2016 63
112. Sharma P, Lok AS. Interferon-free treatment regimens for hepatitis C: are we there yet?
Gastroenterol 141: 1963-7, 2011. PMID: 22033188.
113. Scaglione SJ, Lok AS. Effectiveness of Hepatitis B Treatment in Clinical Practice.
Gastroenterol 142: 1360-8, 2012. PMID: 22537444.
114. Mutimer D, Lok ASF. Management of HBV and HCV Induced End Stage Liver Disease.
Gut; 61 (suppl 1): i59-i67, 2012. PMID: 22504920.
115. Lok AS, Pawlotsky JM. Viral hepatitis at a crossroad. Gastroenterol 142: 1261-3, 2012.
PMID: 22537431.
116. Lok ASF, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B
during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med;
156: 743-5, 2012. PMC3469313
117. Lok ASF. Does antiviral therapy prevent recurrence of hepatitis B virus related
hepatocellular carcinoma after curative liver resection? (invited editorial) JAMA 308:
1922-4, 2012. PMID: 23147511.
118. Lok ASF. HCV NS5A Inhibitors in Development. Clin Liver Dis 17: 111-121, 2013.
119. Lok AS. Long-term therapy of chronic hepatitis B reverses cirrhosis. Nature Rev
Gastroenterol & Hepatol; 10: 199-200, 2013. PMID: 23358397.
120. Kanwal K, Lok AS, El-Serag HB. CDC and USPSTF 2012 Recommendations for
Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages.
Gastroenterol; 144: 478-81, 2013. PMID: 23419454. Clin Gastroenterol Hepatol; 11:
200-3, 2013. PMID: 23432900.
121. Lok AS. Combination nucleos(t)ide analogues as initial treatment for chronic hepatitis B:
Have we put this to rest? (invited editorial) Hepatology 58:483-5, 2013. PMID:
23423734.
122. Yapali S, Talaat N, Lok AS. Management of Hepatitis B: Our Practice and how it relates
to the Guidelines. Clin Gastroenterol Hepatol 12: 16-26, 2014. PMID: 23660419.
123. Yapali S, Lok AS. Should treatment of hepatitis B patients be based solely on liver
fibrosis? Clin Gastroenterol Hepatol, 11: 1500-2, 2013. PMID: 23891926.
124. Hwang JP and Lok ASF. Management of patients with hepatitis B who require
Anna Suk-Fong Lok 12/5/2016 64
immunosuppressive therapy. Nature Rev Gastroenterol & Hepatol 11: 209-19, 2014.
PMC4170710
125. Yapali S and Lok AS. Potential benefit of telbivudine on renal function does not
outweigh its high rate of antiviral drug resistance and other adverse effects. Gastroenterol
(invited editorial) 146: 15-9, 2014. PMID: 24275236.
126. Trepo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet; 384: 2053-63, 2014.
PMID: 24954675.
127. Wei L and Lok ASF. Impact of new hepatitis C treatments in different regions of the
world. Gastroenterol 146:1145-50, 2014. PMID: 24662488.
128. Lok ASF. Progress in hepatitis B: a 30-year journey through three continents. Hepatology
60: 4-11, 2014. PMID: 24619499.
129. Yapali S and Lok AS. Does suppression of HBV replication by antiviral therapy confer
the same benefit as host immune control of HBV? Gut (invited editorial) 63:1833-4,
2014. PMID: 24691291.
130. Konerman MA and Lok AS. Diagnostic challenges of hepatitis C. JAMA 311: 2536-7,
2014. PMC4250928
131. Konerman MA and Lok AS. Is it more cost effective for patients with chronic hepatitis B
to have a trial of interferon before considering nucleos(t)ide analogue therapy? Clin
Gastroenterol and Hepatol (invited editorial) 13: 386-9, 2015. PMID 25158927.
132. Di Bisceglie AM, Lok AS, Martin P, Terrualt N, /Perrillo RP, Hoofnagle JH. Recent FDA
warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just
the tip of the iceberg? Hepatology 61: 703-711, 2015. PMID: 25412906.
133. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to
immunosuppressive drug treatments. JAMA 313: 1617-8, 2015. PMID: 25790287.
134. Lok AS. Personalized treatment of hepatitis B. Clin Mol Hepatol 21: 1-6, 2015.
PMV4379190
135. Locarnini S, Hatzakis A, Chen DS, Lok AS. Strategies to control hepatitis B: public
policy, epidemiology, vaccine and drugs. J Hepatol; 62 (1S):S76-S86, 2015. PMID:
25920093.
136. Lok AS. Hepatitis B: 50 years after the discovery of Australia antigen. J Viral Hepat 23:
Anna Suk-Fong Lok 12/5/2016 65
5-14, 2016. PMID: 26280668.
137. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim
F, Chang KM, Lok AS. Present and future therapies of hepatitis B: From discovery to
cure. Hepatology; 62: 1893-1908, 2015. PMID: 26239691.
138. Konerman MA and Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis; 20: 645-
665, 2016. PMID: 27742005.
139. Konerman MA and Lok AS. Hepatitis C treatment and barriers to disease eradication.
Clin Transl Gastroenterol; 7 (9): e193, 2016. PMID: 27657495.
Books
1. Sherlock’s Diseases of the Liver and Biliary System, ed. J Dooley, AS Lok, AK
Burroughs, EJ Heathcote. Wiley, 12th
edition, 2011.
2. Viral Hepatitis, ed. Thomas HC, Lok ASF, Locarnini SA, Zuckerman AJ. Wiley
Blackwell, 4th
edition, 2013.
Guest Editor
1. Lok ASF, Villamil FG, McDiarmid SV. Liver Transplantation for Viral Hepatitis. Liver
Transplantation, Vol 8, no. 10, supplement; 2002
2. Lok ASF. Hepatitis B. Seminars in Liver Disease Volume 23, number 1, 2003
3. Lok ASF and Schiff ER. The dawn of a new era: transforming our domestic response to
hepatitis B & C. J Family Practice Volume 59, number 4 (supplement), 2010.
Chapters in Books
1. Thomas HC and Lok ASF. Approaches to the treatment of chronic hepatitis B virus
infection. In Advances in Hepatitis Research, ed. Chisari F, Massons Publishing Inc.
27:241-50.
2. Thomas HC and Lok ASF. Treatment of chronic hepatitis B virus infection. In Delta
infection and Viral Hepatitis, ed. Verme G, Bonino F and Rizzetto M, Alan R Liss Inc.
pp: 379-96.
3. Lai CL, Wu PC, Yeoh EK, Lok ASF, Lin HJ, Lam SK and Todd D. Hepatocellular
Carcinoma and the Hepatitis B Virus. In Viral Hepatitis Infection in the Western Pacific
Anna Suk-Fong Lok 12/5/2016 66
Region: Vaccine and control, ed. Lam SK, Lai CL and Yeoh EK. World Scientific Pub;
pp: 3-18.
4. Davis GL, Lok ASF, Schiff ER. Special issues in the treatment of chronic viral hepatitis
with alpha interferon. In Viral Hepatitis and Liver Disease, ed. Hollinger FB, Lemon SM,
Margolis HS, Williams and Wilkins, Baltimore pp: 823-7, 1991.
5. Lok ASF. Interferon therapy in chronic hepatitis B. In “Update on gastrointestinal and
hepatobiliary disorders”, ed. Kurathong S, Wongpaitoon V, Akarawong K. Bangkok
Medical Publisher, Thailand pp: 12-23, 1992.
6. Geders JM, Lok ASF. Interferon therapy for atypical or unusual patients with chronic
viral hepatitis. In Therapy of Liver Diseases, ed. J Rodes and V Arroyo, Masson-Little,
Brown and Co. pp: 187-94, 1995.
7. Lok ASF, Bozkaya H, Ayola B. Hepatitis B virus pre-core/core gene mutants:
epidemiology. In Viral Hepatitis and Liver Disease, ed. M Rizzetto. Purcell RH, Genin
JH, Venne G, Edizoni Minerva Medila, Turin, pp 104-107, 1997.
8. Negro F, Lok ASF. Chronic Viral Hepatitis. In Clinical Practice of Gastroenterology. ed.
LJ Brandt. Current Medicine Inc., Churchill Livingstone, Ch 94, pp 839-848, 1998.
9. Chan HLY, Ghany MG, Lok ASF. Hepatitis B In “Schiff’s Diseases of the Liver”, ed. ER
Schiff, M Sorrell, W Maddrey. Lippincott-Raven Press., 8th
edition Ch 29, pp 757-792,
1998.
10. Chan HLY and Lok ASF. Viral hepatitis B and D. In ‘Principles of Clinical Hepatology’
ed. O’Grady J, Lake J, Howdle P. Harcourt Publishers, Ch. 3 pp 121-122, 2000.
11. Lok ASF. Treatment of chronic hepatitis B virus infection. In Therapy of Liver Diseases,
ed. J Rodes and V Arroyo, Masson-Little, Brown and Co. pp 261-268, 1999.
12. Hussain KB, Lok ASF. Hepatitis B Virology: Acute and Chronic Infection-Wild type
HBV and HBV variants. In Viral Hepatitis ed. S. Gordon, Marcel Dekker Inc. Ch 1, pp 1-
32, 2001.
13. Teo EK, Lok ASF. Treatment of Chronic hepatitis B. In Chronic Viral Hepatitis, ed. R
Koff, G Wu, Humana Press Inc. Ch 7, pp 123-144, 2001.
Anna Suk-Fong Lok 12/5/2016 67
14. Lok ASF. Treatment of hepatitis B e antigen position, chronic hepatitis. In Viral Hepatitis
ed. M. Buti, R Esteban, J Guardia, Accion Medica, Spain, pg 47-56, 2000.
15. Fontana RJ, Lok ASF. Hepatitis B. In Evidence-Based Gastroenterology, ed. EJ Irvine
and RH Hunt, BC Decker, Hamilton, Canada, Ch 27, pp 377-394, 2001.
16. Lok ASF. New Treatment of Chronic Hepatitis B. Therapy in Hepatology, ed. V Arroyo,
P Gines, J Bosch, M Navara, J Bruix, and J Rodes. An Medica, Spain, pp 245-250, 2001.
17. Lok ASF, Conjeevaram H. Hepatitis B In Schiff’s Diseases of the Liver, ed. ER Schiff, M
Sorrell, W Maddrey. Lippincott, Williams and Wilkins, 9th
Edition, Ch. 27, pg 763-806,
2002.
18. Lok ASF. New treatment of chronic hepatitis B. In Viral Hepatitis, ed. M Buti, R
Esteban. Accion Medica, Spain, pg 59-66, 2003.
19. Lok ASF. Treatment of Chronic Hepatitis B – 2003. In Progress in the Treatment of Liver
Diseases, ed. Arroyo V, Forns X, Garcia-Pagan JC, Rodes J. Ars Medica, Spain, pg 113-
120, 2003.
20. Lok ASF. Is viral clearance a realistic goal in the treatment of chronic viral hepatitis. In
Viral Hepatitis and Liver Disease, ed. Jilbert AR, Grgacic EV, Vickery K, Burrell CJ,
Cossart YE. Australian Centre for Hepatitis Virology, pg 156-162, 2004.
21. Marrero JA, Lok AS. Primary Hepatic Neoplasm. In Advanced Therapy in
Gastroenterology and Liver Disease, ed. Bayless and Diehl. B.C. Decker, Hamilton,
Canada, pg 732-8, 2005.
22. Lok ASF, Conjeevaram H and Negro F. Hepatitis B and D. In Schiff’s Diseases of the
Liver, ed. ER Schiff, M Sorrell, W Maddrey. Lippincott, Williams and Wilkins, 10th
Edition Ch 29, pg 745-806, 2006.
23. Degertekin B and Lok ASF. Management of Patients with Antiviral Drug-Resistant HBV.
In Viral Hepatitis, ed. M Buti and R Esteban, pg 130-141, 2008.
24. Lemon SM, Lok A, and Alter MJ. Viral Hepatitis. In Sexually Transmitted Diseases. ed.
K. Holmes, P. Sparling, W. Stamm, P. Piot, J. Wasserheit, L. Corey, M. Cohen, D. Watts.
McGraw Hill, pg 509-543, 2008.
24. Lok ASF and Negro F. Hepatitis B and D. In Schiff’s Diseases of the Liver, ed. ER
Anna Suk-Fong Lok 12/5/2016 68
Schiff, M Sorrell, W Maddrey. Wiley, 11th
edition, Chapter 24, pg 537-581, 2011.
25. Lok ASF. Hepatitis B. In Sherlock’s Diseases of the Liver and Biliary System, ed. J
Dooley, AS Lok, AK Burroughs, EJ Heathcote. Wiley, 12th
edition, Chapter 18, pg 367-
392, 2011.
26. Conjeevaram HS and Lok AS. Hepatitis B and C in non-liver transplant patients. In
Zakim and Boyer’s Hepatology: A Textbook of Liver Diseases. Elsevier, 6th
edition,
Chapter 39, pg 700-717, 2011.
27. Kwon HK and Lok ASF. Treatment of Hepatitis B. In Viral Hepatitis, ed. Thomas HC,
Lok ASF, Locarnini SA, Zuckerman AJ. Wiley Blackwell, 4th edition, Chapter 14, pg
188-202, 2013.
28. Konerman MA and Lok AS. Epidemiology, Diagnosis and Natural History of Hepatitis B.
In Zakim and Boyer’s Hepatology: A Textbook of Liver Diseases. Elsevier, 7th
edition,
eds A Sanyal, N Terrault and K Lindor, Chapter 32, 2016 (in press).
On-Line Publications / Audio-Visual
Uptodate
AV1. Negro F., Lok ASF. Diagnosis of hepatitis D virus infection.
AV2. Negro F, Lok ASF. Pathogenesis and clinical manifestations of hepatitis D virus
infection.
AV3. Negro F, Lok ASF. Treatment and prevention of hepatitis D virus infection.
AV4. Lok ASF. Hepatitis D virus infection following liver transplantation.
AV5. Lok ASF. Standard and pegylated interferon therapy for chronic hepatitis B virus
infection.
AV6. Lok ASF. Liver transplantation for chronic hepatitis B.
AV7. Lok ASF. Investigational treatment of chronic hepatitis B.
AV8. Lok ASF. Clinical manifestations and natural history of hepatitis B virus infection.
AV9. Teo EK, Lok ASF. Epidemiology, transmission and prevention of hepatitis B virus
infection.
AV10. Lok ASF. Serologic diagnosis of hepatitis B.
AV11. Lok ASF. Characteristics of the hepatitis B virus and pathogenesis of infection.
AV12. Chan TM, Lok ASF. Renal diseases associated with hepatitis B virus infection.
AV13. Lok ASF. Lamivudine monotherapy in the treatment of chronic hepatitis B.
AV14. Teo EK, Lok ASF. Hepatitis B Vaccination
AV15. Chu, CJ, Lok, ASF. Clinical significance of HBV genotypes.
AV16. Chu, CJ, Lok, ASF. Clinical significance and molecular characteristics of common HBV
Anna Suk-Fong Lok 12/5/2016 69
variants.
AV17. Lok ASF. Adefovir dipivoxil treatment of chronic hepatitis B.
AV18. Lok ASF. Combination therapy of chronic hepatitis B.
AV19. Lok ASF. Entecavir in the treatment of chronic hepatitis B.
AV20. Lok ASF. Telbivudine in the treatment of chronic hepatitis B.
AV21. Lok ASF. Tenofovir in the treatment of adults with chronic HBV infection who do not
have HIV infection.
AV22. Lok ASF and Bonis P. HBV reactivation associated with immunosuppression.
AV23. Lok ASF. Overview of the management of hepatitis B and case examples.
AV24. Rose BD and Lok ASF. Hepatitis B virus and renal transplant recipients.
AV25. Lee H and Lok ASF. Hepatitis B and pregnancy.
Clinical Liver Disease
Editor: Hepatitis B, Volume 2, Issue 1, 2013
Lok ASF. New all-oral HCV therapies for genotype 1: a final good-bye to interferon, 2014.
Kwon H and Lok AS. Viral Hepatitis and Pregnancy, 2014.